Holland-Frei Cancer Medicine

 
 
Standards Information Network (Verlag)
  • 9. Auflage
  • |
  • erschienen am 10. März 2017
  • |
  • 2008 Seiten
 
E-Book | PDF mit Adobe-DRM | Systemvoraussetzungen
978-1-119-00084-6 (ISBN)
 
Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients.
* A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease
* An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies
* Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics
* Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs
* Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates
9. Auflage
  • Englisch
  • Somerset
  • |
  • USA
John Wiley & Sons Inc
  • Für Beruf und Forschung
  • Überarbeitete Ausgabe
  • 154,16 MB
978-1-119-00084-6 (9781119000846)
weitere Ausgaben werden ermittelt
Robert C. Bast Jr, MD, Vice President for Translational Research, MD Anderson Cancer Center, Houston, TX, USA
Carlo M. Croce, MD, Distinguished University Professor, The John W. Wolfe Chair in Human Cancer Genetics, Professor and Chair, Department of Molecular Virology, Immunology and Medical Genetics, The Wexner Medical Center, The Ohio State University, Columbus, OH, USA
William Hait, MD, PhD, Global Head research and Development, Janssen pharmaceutical companies of Johnson and Johnson, NJ, USA
Waun Ki Hong, MD, DMSc, Professor of Thoracic/Head and Neck Medical Oncology, American Cancer Society Professor, Samsung Distinguished University Chair in Cancer Medicine Emeritus, The University of Texas M.D.Anderson Cancer Center, Houston, TX, USA
Donald W. Kufe, MD, Distinguished Physician, Dana-Farber Cancer Institute, Professor of Medicine
Harvard Medical School, Leader, Translational Pharmacology and Early Therapeutic Trials Program
Dana-Farber/Harvard Cancer Center, Boston, MA, USA
Martine Piccart-Gebhart MD PhD, Professor of Oncology, Université Libre de Bruxelles (ULB), Head of the Medicine Department, Jules Bordet Institute, Brussels, Belgium
Raphael E. Pollock, MD, PhD, FACS, Professor and Director, Division of Surgical Oncology, Surgeon in Chief, James Comprehensive Cancer Center, Surgeon in Chief, The Ohio State University Health System, The Ohio State University Wexner Medical Center, Columbus, OH, USA
Ralph R. Weichselbaum, MD, Daniel K. Ludwig Professor Chair Dept of Radiology and Cellular Oncology University of Chicago Hospital Director Chicago Tumor Institute, IL, USA
Dr Hongyang Wang, Professor and Director, National Center for Liver Cancer, China; and Eastern Hepatobiliary Surgery Hospital, Shanghai, China
James F. Holland, MD, ScD (hc), Distinguished Professor of Neoplastic Diseases, Director Emeritus of Derald H.Rutttenberg Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA
ASSOCIATE EDITORFadlo R. Khuri, MD, Executive Associate Dean for Research, Emory University School of Medicine, Atlanta, GA, USA; President, the American University of Beirut, Beirut, Lebanon
1 - Cover???????????????????????? [Seite 1]
2 - Title Page?????????????????????????????????? [Seite 5]
3 - Copyright???????????????????????????????? [Seite 6]
4 - Contents?????????????????????????????? [Seite 7]
5 - List of contributors [Seite 13]
6 - Preface [Seite 29]
7 - Acknowledgments [Seite 31]
8 - Part 1 Introduction???????????????????????????????????????????????????? [Seite 33]
8.1 - Chapter 1 Cardinal manifestations of cancer???????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 35]
8.1.1 - The present???????????????????????????????????? [Seite 37]
8.1.2 - The future?????????????????????????????????? [Seite 37]
8.2 - Chapter 2 Biological hallmarks of cancer?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 39]
8.2.1 - Distilling the dauntingly complex manifestations of cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 39]
8.2.2 - Acquired functional capabilities embody biological hallmarks of cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 39]
8.2.3 - Aberrations that enable acquisition of the necessary functional capabilities?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 43]
8.2.4 - The histopathological complexity of cancer, manifested in tumor microenvironments (TMEs)?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 45]
8.2.5 - Therapeutic targeting (and cotargeting) of cancer hallmarks???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 46]
8.2.6 - References?????????????????????????????????? [Seite 48]
9 - Part 2 Tumor Biology?????????????????????????????????????????????????????? [Seite 49]
9.1 - Chapter 3 Molecular biology, genomics, proteomics, and mouse models of human cancer???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 51]
9.1.1 - Overview: gene structure?????????????????????????????????????????????????????????????? [Seite 51]
9.1.2 - General techniques?????????????????????????????????????????????????? [Seite 53]
9.1.3 - Gene expression: mRNA transcript analysis???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 64]
9.1.4 - Epigenetic regulation???????????????????????????????????????????????????????? [Seite 69]
9.1.5 - Gene expression: protein analysis???????????????????????????????????????????????????????????????????????????????? [Seite 70]
9.1.6 - Functional screens for the identification of therapeutic targets in cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 74]
9.1.7 - Mouse models of human cancer?????????????????????????????????????????????????????????????????????? [Seite 75]
9.1.8 - Key references?????????????????????????????????????????? [Seite 77]
9.2 - Chapter 4 Oncogenes???????????????????????????????????????????????????? [Seite 79]
9.2.1 - Discovery and identification of oncogenes???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 79]
9.2.2 - Mechanisms of oncogene activation???????????????????????????????????????????????????????????????????????????????? [Seite 86]
9.2.3 - New markers from large-scale genomic analysis???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 92]
9.2.4 - Oncogenes in the initiation and progression of neoplasia?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 92]
9.2.5 - Oncogenes as target of new drugs?????????????????????????????????????????????????????????????????????????????? [Seite 93]
9.2.6 - Summary and conclusions???????????????????????????????????????????????????????????? [Seite 97]
9.2.7 - Key references?????????????????????????????????????????? [Seite 97]
9.3 - Chapter 5 Tumor suppressor genes?????????????????????????????????????????????????????????????????????????????? [Seite 99]
9.3.1 - Genetic basis for tumor development???????????????????????????????????????????????????????????????????????????????????? [Seite 99]
9.3.2 - Somatic cell genetic studies of tumorigenesis???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 100]
9.3.3 - Retinoblastoma: a paradigm for tumor suppressor gene function???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 100]
9.3.4 - Key references?????????????????????????????????????????? [Seite 114]
9.4 - Chapter 6 Epigenetic contributions to human cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 117]
9.4.1 - Mechanisms involved in epigenetic regulation of gene expression???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 117]
9.4.2 - Altered DNA methylation and chromatin in cancer or the "cancer epigenome"???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 118]
9.4.3 - Clinical implications of altered DNA methylation in cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 120]
9.4.4 - Key references?????????????????????????????????????????? [Seite 122]
9.5 - Chapter 7 Cancer genomics and evolution???????????????????????????????????????????????????????????????????????????????????????????? [Seite 125]
9.5.1 - Precis?????????????????????????? [Seite 125]
9.5.2 - Introduction?????????????????????????????????????? [Seite 125]
9.5.3 - The history and methods of cancer genomics?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 126]
9.5.4 - Cancer genome landscapes?????????????????????????????????????????????????????????????? [Seite 130]
9.5.5 - Cancer evolution?????????????????????????????????????????????? [Seite 136]
9.5.6 - Cancer genomics and evolution in clinical practice: A case study in melanoma?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 140]
9.5.7 - Acknowledgments???????????????????????????????????????????? [Seite 144]
9.5.8 - Glossary?????????????????????????????? [Seite 144]
9.5.9 - Key references?????????????????????????????????????????? [Seite 145]
9.6 - Chapter 8 Chromosomal aberrations in cancer???????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 147]
9.6.1 - Introduction?????????????????????????????????????? [Seite 147]
9.6.2 - Genetic consequences of genomic rearrangements?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 147]
9.6.3 - Chromosome nomenclature???????????????????????????????????????????????????????????? [Seite 148]
9.6.4 - Methods that complement karyotype analysis?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 148]
9.6.5 - Specific clonal disorders???????????????????????????????????????????????????????????????? [Seite 149]
9.6.6 - Key references?????????????????????????????????????????? [Seite 162]
9.7 - Chapter 9 MicroRNA expression in cancer???????????????????????????????????????????????????????????????????????????????????????????? [Seite 163]
9.7.1 - Background?????????????????????????????????? [Seite 163]
9.7.2 - Biogenesis and production of microRNAs?????????????????????????????????????????????????????????????????????????????????????????? [Seite 163]
9.7.3 - MicroRNA deregulation in cancer???????????????????????????????????????????????????????????????????????????? [Seite 164]
9.7.4 - MicroRNA as biomarkers in cancer?????????????????????????????????????????????????????????????????????????????? [Seite 165]
9.7.5 - MicroRNAs as noninvasive biomarkers in cancer???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 165]
9.7.6 - Selected miRNAs implicated in cancer?????????????????????????????????????????????????????????????????????????????????????? [Seite 166]
9.7.7 - Therapeutic targeting and miRNA???????????????????????????????????????????????????????????????????????????? [Seite 166]
9.7.8 - Human applications for miRNAs???????????????????????????????????????????????????????????????????????? [Seite 167]
9.7.9 - References?????????????????????????????????? [Seite 167]
9.8 - Chapter 10 Aberrant signaling pathways in cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 169]
9.8.1 - Growth factor receptors with Tyr kinase activity?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 169]
9.8.2 - Aberrations affecting growth factor receptors in tumor cells?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 171]
9.8.3 - Signaling pathways of Tyr kinase receptors?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 171]
9.8.4 - Other signaling pathways aberrantly deregulated in cancer???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 173]
9.8.5 - Growth factor signaling and cancer therapy?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 174]
9.8.6 - Acknowledgments???????????????????????????????????????????? [Seite 177]
9.8.7 - Key references?????????????????????????????????????????? [Seite 177]
9.9 - Chapter 11 Differentiation therapy?????????????????????????????????????????????????????????????????????????????????? [Seite 179]
9.9.1 - Molecular mechanisms underlying differentiation blockage in cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 179]
9.9.2 - Potential cancer cell differentiation-inducing agents???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 182]
9.9.3 - APL as a successful model of cancer differentiation therapy???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 185]
9.9.4 - Perspectives?????????????????????????????????????? [Seite 188]
9.9.5 - Acknowledgments???????????????????????????????????????????? [Seite 190]
9.9.6 - Key references?????????????????????????????????????????? [Seite 190]
9.10 - Chapter 12 Cancer stem cells?????????????????????????????????????????????????????????????????????? [Seite 191]
9.10.1 - Cancer stem cell hypothesis???????????????????????????????????????????????????????????????????? [Seite 191]
9.10.2 - EMT/MET and cancer stem cells???????????????????????????????????????????????????????????????????????? [Seite 193]
9.10.3 - Signal transduction pathways in cancer stem cells and their therapeutic targeting???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 193]
9.10.4 - Clinical significance of cancer stem cells and future perspectives?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 195]
9.10.5 - Key references?????????????????????????????????????????? [Seite 197]
9.11 - Chapter 13 Cancer and cell death?????????????????????????????????????????????????????????????????????????????? [Seite 199]
9.11.1 - Introduction?????????????????????????????????????? [Seite 199]
9.11.2 - Pathways for cell death???????????????????????????????????????????????????????????? [Seite 199]
9.11.3 - Cell death resistance mechanisms used by cancers?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 203]
9.11.4 - Signal transduction pathway alterations in cancers-impact on cell death machinery???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 205]
9.11.5 - Cytotoxic chemotherapeutic oncology drugs???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 207]
9.11.6 - Cancer drug discovery by targeting the cell death machinery???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 207]
9.11.7 - Conclusions???????????????????????????????????? [Seite 209]
9.11.8 - List of abbreviations???????????????????????????????????????????????????????? [Seite 209]
9.11.9 - Key references?????????????????????????????????????????? [Seite 209]
9.12 - Chapter 14 Cancer cell immortality: targeting telomerase?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 211]
9.12.1 - Telomerase: a universal target for cancer therapy???????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 211]
9.12.2 - There are no telomere/telomerase-targeted drugs approved by the Food and Drug Administration (FDA)?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 213]
9.12.3 - Challenges for developing telomerase inhibitors???????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 216]
9.12.4 - Overexpression of mutant hTERC and wild-type hTERC-targeted siRNA by lentiviral vectors are different types of gene therapy strategies for telomerase-targeted therapies?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 216]
9.12.5 - 6-Thio-dG is a small molecule that is a telomerase-based telomere uncapping target that may overcome some of the problems with gene therapy???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 216]
9.12.6 - Acknowledgments???????????????????????????????????????????? [Seite 218]
9.12.7 - Key references?????????????????????????????????????????? [Seite 218]
9.13 - Chapter 15 Cancer metabolism?????????????????????????????????????????????????????????????????????? [Seite 219]
9.13.1 - Malicious builders?????????????????????????????????????????????????? [Seite 219]
9.13.2 - From yeast to mammals-same means to different ends?????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 219]
9.13.3 - Bad table manners of cancer cells???????????????????????????????????????????????????????????????????????????????? [Seite 221]
9.13.4 - The traveling electrons???????????????????????????????????????????????????????????? [Seite 221]
9.13.5 - Warburg effect-how to play safe while looking sloppy?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 222]
9.13.6 - The cavalry arrives!-glutamine and anabolic metabolism?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 224]
9.13.7 - The nucleus smells what's cooking???????????????????????????????????????????????????????????????????????????????? [Seite 225]
9.13.8 - From petty thieves to ringleaders-how cancer cells corrupt their neighbors?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 226]
9.13.9 - Cancer metabolism comes into the clinic???????????????????????????????????????????????????????????????????????????????????????????? [Seite 227]
9.13.10 - Conclusions???????????????????????????????????? [Seite 228]
9.13.11 - Key references?????????????????????????????????????????? [Seite 228]
9.14 - Chapter 16 Modeling therapy of late or early-stage metastatic disease in mice???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 231]
9.14.1 - Introduction?????????????????????????????????????? [Seite 231]
9.14.2 - Conclusions???????????????????????????????????? [Seite 236]
9.14.3 - Acknowledgments???????????????????????????????????????????? [Seite 236]
9.14.4 - References?????????????????????????????????? [Seite 236]
9.15 - Chapter 17 Tumor angiogenesis???????????????????????????????????????????????????????????????????????? [Seite 239]
9.15.1 - Tumor angiogenesis?????????????????????????????????????????????????? [Seite 239]
9.15.2 - Rationale for targeting tumor vasculature???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 239]
9.15.3 - Historic background???????????????????????????????????????????????????? [Seite 240]
9.15.4 - Biology of tumor angiogenesis???????????????????????????????????????????????????????????????????????? [Seite 241]
9.15.5 - Regulators of angiogenesis?????????????????????????????????????????????????????????????????? [Seite 242]
9.15.6 - Therapeutic approaches to targeting tumor vasculature???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 249]
9.15.7 - Clinical advances in the use of antiangiogenic therapy?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 251]
9.15.8 - Lessons from clinical studies of antiangiogenic therapy and future directions???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 258]
9.15.9 - Concluding remarks?????????????????????????????????????????????????? [Seite 261]
9.15.10 - Acknowledgments???????????????????????????????????????????? [Seite 261]
9.15.11 - Key references?????????????????????????????????????????? [Seite 261]
10 - Part 3 Quantitative Oncology?????????????????????????????????????????????????????????????????????? [Seite 263]
10.1 - Chapter 18 Cancer bioinformatics?????????????????????????????????????????????????????????????????????????????? [Seite 265]
10.1.1 - The definition and scope of bioinformatics?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 266]
10.1.2 - The analog (microarray) to digital (sequencing) transition?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 266]
10.1.3 - Bioinformatic analysis, visualization, and interpretation???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 269]
10.1.4 - Hypothesis-generating and hypothesis-driven research?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 270]
10.1.5 - Analysis and biointerpretation in major molecular profiling projects?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 272]
10.1.6 - Statistical methods and associated pitfalls???????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 273]
10.1.7 - References?????????????????????????????????? [Seite 278]
10.2 - Chapter 19 Systems biology and genomics???????????????????????????????????????????????????????????????????????????????????????????? [Seite 279]
10.2.1 - Introduction?????????????????????????????????????? [Seite 279]
10.2.2 - Intrinsic systems biology and genomics in cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 279]
10.2.3 - Tumor microenvironment?????????????????????????????????????????????????????????? [Seite 283]
10.2.4 - Conclusion?????????????????????????????????? [Seite 285]
10.2.5 - Acknowledgments???????????????????????????????????????????? [Seite 286]
10.2.6 - Key references?????????????????????????????????????????? [Seite 286]
10.3 - Chapter 20 Statistical innovations in cancer research???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 287]
10.3.1 - Preliminaries???????????????????????????????????????? [Seite 288]
10.3.2 - Bayesian approach???????????????????????????????????????????????? [Seite 288]
10.3.3 - Analysis issues???????????????????????????????????????????? [Seite 292]
10.3.4 - Principles of statistical design: decision analysis and factorial experiments???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 295]
10.3.5 - Adaptive designs of clinical trials???????????????????????????????????????????????????????????????????????????????????? [Seite 296]
10.3.6 - Acknowledgments???????????????????????????????????????????? [Seite 302]
10.3.7 - Key references?????????????????????????????????????????? [Seite 302]
10.4 - Chapter 21 Biomarker-based clinical trial design in the era of genomic medicine???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 303]
10.4.1 - Introduction: why we need new designs and analysis paradigms for biomarker-driven clinical trials???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 303]
10.4.2 - Phase II trials of molecularly targeted agents with companion diagnostics???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 303]
10.4.3 - Phase IIa basket and umbrella discovery trials?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 304]
10.4.4 - Phase III designs with a single binary biomarker?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 305]
10.4.5 - Phase II/III enrichment designs with multiple biomarkers?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 308]
10.4.6 - The new models of collaboration required by clinical trials of the "genomic era" and the challenges ahead???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 308]
10.4.7 - Conclusion?????????????????????????????????? [Seite 308]
10.4.8 - References?????????????????????????????????? [Seite 308]
10.5 - Chapter 22 Clinical informatics???????????????????????????????????????????????????????????????????????????? [Seite 309]
10.5.1 - Introduction?????????????????????????????????????? [Seite 309]
10.5.2 - An oncology digital health information technology system?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 309]
10.5.3 - The mobile computing revolution???????????????????????????????????????????????????????????????????????????? [Seite 313]
10.5.4 - References?????????????????????????????????? [Seite 314]
11 - Part 4 Carcinogenesis???????????????????????????????????????????????????????? [Seite 317]
11.1 - Chapter 23 Chemical carcinogenesis?????????????????????????????????????????????????????????????????????????????????? [Seite 319]
11.1.1 - Multistage carcinogenesis???????????????????????????????????????????????????????????????? [Seite 319]
11.1.2 - Epigenetics and chemical carcinogenesis???????????????????????????????????????????????????????????????????????????????????????????? [Seite 322]
11.1.3 - miRNA's in chemical carcinogenesis?????????????????????????????????????????????????????????????????????????????????? [Seite 323]
11.1.4 - Gene-environment interactions and inter-individual variation?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 325]
11.1.5 - Carcinogen metabolism???????????????????????????????????????????????????????? [Seite 326]
11.1.6 - DNA damage and repair???????????????????????????????????????????????????????? [Seite 328]
11.1.7 - Mutator phenotype???????????????????????????????????????????????? [Seite 329]
11.1.8 - Racial, gender, and socioeconomic disparities in chemical carcinogenesis?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 329]
11.1.9 - Chronic inflammation and cancer???????????????????????????????????????????????????????????????????????????? [Seite 331]
11.1.10 - Oncogenes and tumor suppressor genes?????????????????????????????????????????????????????????????????????????????????????? [Seite 332]
11.1.11 - Precision medicine, molecular epidemiology, and prevention?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 333]
11.1.12 - Acknowledgments???????????????????????????????????????????? [Seite 337]
11.1.13 - Key references?????????????????????????????????????????? [Seite 337]
11.2 - Chapter 24 Endocrine and genetic bases of hormone-related cancers???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 339]
11.2.1 - Breast cancer???????????????????????????????????????? [Seite 339]
11.2.2 - Endometrial cancer?????????????????????????????????????????????????? [Seite 344]
11.2.3 - Ovarian cancer?????????????????????????????????????????? [Seite 346]
11.2.4 - Prostate cancer???????????????????????????????????????????? [Seite 347]
11.2.5 - Genetic determinants?????????????????????????????????????????????????????? [Seite 348]
11.2.6 - Conclusions???????????????????????????????????? [Seite 350]
11.2.7 - Key references?????????????????????????????????????????? [Seite 350]
11.3 - Chapter 25 Ionizing radiation???????????????????????????????????????????????????????????????????????? [Seite 353]
11.3.1 - Development of radiation injury???????????????????????????????????????????????????????????????????????????? [Seite 353]
11.3.2 - Principal cellular and tissue effects of radiation?????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 353]
11.3.3 - Chromosomal aberrations???????????????????????????????????????????????????????????? [Seite 354]
11.3.4 - DNA damage?????????????????????????????????? [Seite 355]
11.3.5 - General characteristics of radiation carcinogenesis???????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 355]
11.3.6 - Genetic susceptibility to radiation-induced cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 356]
11.3.7 - Human epidemiologic studies???????????????????????????????????????????????????????????????????? [Seite 356]
11.3.8 - Acknowledgments???????????????????????????????????????????? [Seite 357]
11.3.9 - Key references?????????????????????????????????????????? [Seite 357]
11.4 - Chapter 26 Ultraviolet radiation carcinogenesis???????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 359]
11.4.1 - Epidemiology of skin cancer???????????????????????????????????????????????????????????????????? [Seite 359]
11.4.2 - Genetic factors in skin carcinogenesis?????????????????????????????????????????????????????????????????????????????????????????? [Seite 360]
11.4.3 - Diseases of DNA repair?????????????????????????????????????????????????????????? [Seite 361]
11.4.4 - Carcinogenesis?????????????????????????????????????????? [Seite 362]
11.4.5 - Acknowledgments???????????????????????????????????????????? [Seite 363]
11.4.6 - Key references?????????????????????????????????????????? [Seite 363]
11.5 - Chapter 27 Inflammation and cancer?????????????????????????????????????????????????????????????????????????????????? [Seite 365]
11.5.1 - Chronic inflammation and cancer???????????????????????????????????????????????????????????????????????????? [Seite 365]
11.5.2 - Inflammatory cells, the microenvironment, and cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 365]
11.5.3 - Pro- and anti-inflammatory cytokines in cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 366]
11.5.4 - Inflammation and tumorigenesis?????????????????????????????????????????????????????????????????????????? [Seite 368]
11.5.5 - Inflammation-dependent cancers-examples and treatment???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 369]
11.5.6 - Key references?????????????????????????????????????????? [Seite 370]
11.6 - Chapter 28 RNA tumor viruses?????????????????????????????????????????????????????????????????????? [Seite 373]
11.6.1 - Classification?????????????????????????????????????????? [Seite 373]
11.6.2 - Structure???????????????????????????????? [Seite 373]
11.6.3 - Viral genome and gene products?????????????????????????????????????????????????????????????????????????? [Seite 374]
11.6.4 - Genomic variation???????????????????????????????????????????????? [Seite 374]
11.6.5 - Replication cycle???????????????????????????????????????????????? [Seite 374]
11.6.6 - Mechanisms of oncogenesis???????????????????????????????????????????????????????????????? [Seite 374]
11.6.7 - Oncogene capture?????????????????????????????????????????????? [Seite 375]
11.6.8 - Insertional mutagenesis???????????????????????????????????????????????????????????? [Seite 376]
11.6.9 - Growth stimulation and two-step oncogenesis???????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 377]
11.6.10 - Transactivation???????????????????????????????????????????? [Seite 378]
11.6.11 - Human immunodeficiency virus?????????????????????????????????????????????????????????????????????? [Seite 380]
11.6.12 - Endogenous retroviruses???????????????????????????????????????????????????????????? [Seite 380]
11.6.13 - Retroviral vectors and gene therapy???????????????????????????????????????????????????????????????????????????????????? [Seite 382]
11.6.14 - Conclusions???????????????????????????????????? [Seite 383]
11.6.15 - Key references?????????????????????????????????????????? [Seite 383]
11.7 - Chapter 29 Herpesviruses?????????????????????????????????????????????????????????????? [Seite 385]
11.7.1 - Properties of herpesviruses???????????????????????????????????????????????????????????????????? [Seite 385]
11.7.2 - EBV: an oncogenic human herpesvirus???????????????????????????????????????????????????????????????????????????????????? [Seite 385]
11.7.3 - KSHV and malignancies???????????????????????????????????????????????????????? [Seite 388]
11.7.4 - Key references?????????????????????????????????????????? [Seite 390]
11.8 - Chapter 30 Papillomaviruses and cervical neoplasia?????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 393]
11.8.1 - Definitions, HPV-target cells, and mechanisms of infection and transformation???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 393]
11.8.2 - HPV and human genital neoplasia???????????????????????????????????????????????????????????????????????????? [Seite 395]
11.8.3 - Key references?????????????????????????????????????????? [Seite 397]
11.9 - Chapter 31 Hepatitis viruses and hepatoma???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 399]
11.9.1 - Hepatitis and hepatoma?????????????????????????????????????????????????????????? [Seite 399]
11.9.2 - Key references?????????????????????????????????????????? [Seite 403]
11.10 - Chapter 32 Parasites?????????????????????????????????????????????????????? [Seite 405]
11.10.1 - Schistosomiasis and cancer of the bladder???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 405]
11.10.2 - Epidemiologic aspects???????????????????????????????????????????????????????? [Seite 405]
11.10.3 - Progression of bilharzial bladder cancer?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 406]
11.10.4 - Human papilloma virus???????????????????????????????????????????????????????? [Seite 406]
11.10.5 - Metabolic observations during schistosomiasis???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 406]
11.10.6 - Apoptosis in schistosomal bladder cancer?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 407]
11.10.7 - Pathology of benign and preneoplastic schistosomal bladder lesions?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 407]
11.10.8 - Experimental data for BBC???????????????????????????????????????????????????????????????? [Seite 407]
11.10.9 - Schistosomiasis and cancer of other sites???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 408]
11.10.10 - Evaluation of carcinogenicity of schistosomiasis?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 408]
11.10.11 - East Asian distomiasis?????????????????????????????????????????????????????????? [Seite 408]
11.10.12 - Malaria???????????????????????????? [Seite 409]
11.10.13 - Recent evidences?????????????????????????????????????????????? [Seite 410]
11.10.14 - Key references?????????????????????????????????????????? [Seite 410]
12 - Part 5 Epidemiology, Prevention and Detection???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 413]
12.1 - Chapter 33 The burden of cancer worldwide: current and future perspectives?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 415]
12.1.1 - Introduction?????????????????????????????????????? [Seite 415]
12.1.2 - Definitions, data sources, and methods?????????????????????????????????????????????????????????????????????????????????????????? [Seite 415]
12.1.3 - Global cancer diversity???????????????????????????????????????????????????????????? [Seite 416]
12.1.4 - Global cancer transitions???????????????????????????????????????????????????????????????? [Seite 426]
12.1.5 - Using descriptive epidemiology to inform cancer control policy?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 428]
12.1.6 - Acknowledgments???????????????????????????????????????????? [Seite 428]
12.1.7 - References?????????????????????????????????? [Seite 428]
12.2 - Chapter 34 Cancer epidemiology?????????????????????????????????????????????????????????????????????????? [Seite 431]
12.2.1 - Descriptive cancer statistics???????????????????????????????????????????????????????????????????????? [Seite 431]
12.2.2 - Cancer health disparities???????????????????????????????????????????????????????????????? [Seite 431]
12.2.3 - Emerging cancer risk factors?????????????????????????????????????????????????????????????????????? [Seite 433]
12.2.4 - Genetic susceptibility?????????????????????????????????????????????????????????? [Seite 434]
12.2.5 - Emerging methods and technologies???????????????????????????????????????????????????????????????????????????????? [Seite 435]
12.2.6 - Perspective and future direction?????????????????????????????????????????????????????????????????????????????? [Seite 436]
12.2.7 - Key references?????????????????????????????????????????? [Seite 437]
12.3 - Chapter 35 Behavioral approaches to cancer prevention???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 439]
12.3.1 - Tobacco use???????????????????????????????????? [Seite 439]
12.3.2 - Energy balance: diet, physical activity, and body weight?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 440]
12.3.3 - Risk behaviors for skin cancer?????????????????????????????????????????????????????????????????????????? [Seite 444]
12.3.4 - Key references?????????????????????????????????????????? [Seite 444]
12.4 - Chapter 36 Diet and nutrition in the etiology and prevention of cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 447]
12.4.1 - Methodologic issues in diet, nutrition, and cancer studies?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 449]
12.4.2 - Public health guidelines for cancer prevention?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 450]
12.4.3 - Summary of research efforts focusing on specific cancers?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 452]
12.4.4 - Current research?????????????????????????????????????????????? [Seite 458]
12.4.5 - Survivorship: diet and nutritional guidance during and following cancer treatment???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 461]
12.4.6 - Prevention of cancer recurrences and long-term complication of therapy?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 462]
12.4.7 - Key references?????????????????????????????????????????? [Seite 463]
12.5 - Chapter 37 Chemoprevention of cancer?????????????????????????????????????????????????????????????????????????????????????? [Seite 465]
12.5.1 - Biology of chemoprevention?????????????????????????????????????????????????????????????????? [Seite 465]
12.5.2 - Cancer risk modeling?????????????????????????????????????????????????????? [Seite 465]
12.5.3 - Chemoprevention trials?????????????????????????????????????????????????????????? [Seite 465]
12.5.4 - Conclusions???????????????????????????????????? [Seite 468]
12.5.5 - Key references?????????????????????????????????????????? [Seite 469]
12.6 - Chapter 38 Cancer screening and early detection???????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 471]
12.6.1 - Key criteria for screening?????????????????????????????????????????????????????????????????? [Seite 471]
12.6.2 - Evaluation of early detection programs?????????????????????????????????????????????????????????????????????????????????????????? [Seite 471]
12.6.3 - Breast cancer screening???????????????????????????????????????????????????????????? [Seite 473]
12.6.4 - Colorectal cancer???????????????????????????????????????????????? [Seite 477]
12.6.5 - Cervical cancer???????????????????????????????????????????? [Seite 479]
12.6.6 - Prostate cancer???????????????????????????????????????????? [Seite 481]
12.6.7 - Lung cancer???????????????????????????????????? [Seite 483]
12.6.8 - Testicular cancer???????????????????????????????????????????????? [Seite 484]
12.6.9 - Hepatocellular cancer???????????????????????????????????????????????????????? [Seite 484]
12.6.10 - Endometrial cancer?????????????????????????????????????????????????? [Seite 484]
12.6.11 - Ovarian cancer?????????????????????????????????????????? [Seite 484]
12.6.12 - Melanoma and nonmelanoma skin cancer?????????????????????????????????????????????????????????????????????????????????????? [Seite 485]
12.6.13 - Oral cancer???????????????????????????????????? [Seite 486]
12.6.14 - Conclusion?????????????????????????????????? [Seite 486]
12.6.15 - Key references?????????????????????????????????????????? [Seite 486]
13 - Part 6 Clinical Disciplines???????????????????????????????????????????????????????????????????? [Seite 489]
13.1 - Chapter 39 Nexgen pathology: predicting clinical course and targeting disease causation???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 491]
13.1.1 - From anatomic and clinical pathology to molecular and predictive integrated diagnostics???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 491]
13.1.2 - Molecular pathology???????????????????????????????????????????????????? [Seite 492]
13.1.3 - Bladder cancer as a model of molecular pathology classification???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 493]
13.1.4 - Systems pathology and predictive oncology???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 494]
13.1.5 - From treating symptomatology to treating disease causation?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 496]
13.1.6 - References?????????????????????????????????? [Seite 498]
13.2 - Chapter 40 Molecular diagnostics in cancer?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 501]
13.2.1 - Introduction?????????????????????????????????????? [Seite 501]
13.2.2 - Current molecular biomarkers for predicting outcomes and therapy responsiveness???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 504]
13.2.3 - Molecular biomarkers for monitoring of cancer???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 506]
13.2.4 - Novel molecular biomarkers and platforms for their detection?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 507]
13.2.5 - Challenges in validation of novel molecular biomarkers?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 510]
13.2.6 - Recommendations???????????????????????????????????????????? [Seite 510]
13.2.7 - Conclusion?????????????????????????????????? [Seite 511]
13.2.8 - Key references?????????????????????????????????????????? [Seite 511]
13.3 - Chapter 41 Principles of imaging?????????????????????????????????????????????????????????????????????????????? [Seite 513]
13.3.1 - Further reading???????????????????????????????????????????? [Seite 513]
13.4 - Chapter 42 Interventional radiology for the cancer patient?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 515]
13.4.1 - Hepatic vascular interventions?????????????????????????????????????????????????????????????????????????? [Seite 515]
13.4.2 - Considerations in hepatocellular carcinoma?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 518]
13.4.3 - Considerations in hepatic metastases?????????????????????????????????????????????????????????????????????????????????????? [Seite 518]
13.4.4 - Genitourinary interventions???????????????????????????????????????????????????????????????????? [Seite 519]
13.4.5 - Thoracic interventions?????????????????????????????????????????????????????????? [Seite 520]
13.4.6 - Palliative therapy?????????????????????????????????????????????????? [Seite 520]
13.4.7 - Miscellaneous???????????????????????????????????????? [Seite 521]
13.4.8 - Key references?????????????????????????????????????????? [Seite 521]
13.5 - Chapter 43 Principles of surgical oncology?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 523]
13.5.1 - The history of surgical oncology?????????????????????????????????????????????????????????????????????????????? [Seite 524]
13.5.2 - Surgical oncology in the modern era???????????????????????????????????????????????????????????????????????????????????? [Seite 526]
13.5.3 - Components of surgical management in the care of the cancer patient???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 528]
13.5.4 - The future of surgical oncology???????????????????????????????????????????????????????????????????????????? [Seite 533]
13.5.5 - References?????????????????????????????????? [Seite 534]
13.6 - Chapter 44 Principles of radiation oncology???????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 535]
13.6.1 - Introduction?????????????????????????????????????? [Seite 535]
13.6.2 - General principles of radiotherapy in cancer treatment?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 535]
13.6.3 - Biologic impact of radiation therapy?????????????????????????????????????????????????????????????????????????????????????? [Seite 536]
13.6.4 - Physical and clinical aspects of modern radiotherapy?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 539]
13.6.5 - Conclusions and future directions in radiotherapy???????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 541]
13.6.6 - Key references?????????????????????????????????????????? [Seite 541]
13.7 - Chapter 45 Principles of medical oncology???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 543]
13.7.1 - Principles?????????????????????????????????? [Seite 543]
13.7.2 - Cancer therapeutics is evolving???????????????????????????????????????????????????????????????????????????? [Seite 546]
13.7.3 - References?????????????????????????????????? [Seite 551]
13.8 - Chapter 46 Palliative care and pain management?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 553]
13.8.1 - Palliative care???????????????????????????????????????????? [Seite 553]
13.8.2 - Whole patient assessment?????????????????????????????????????????????????????????????? [Seite 553]
13.8.3 - Communication???????????????????????????????????????? [Seite 553]
13.8.4 - Advance care planning???????????????????????????????????????????????????????? [Seite 554]
13.8.5 - Symptom management?????????????????????????????????????????????????? [Seite 555]
13.8.6 - The terminal phase?????????????????????????????????????????????????? [Seite 558]
13.8.7 - Grief and bereavement???????????????????????????????????????????????????????? [Seite 560]
13.8.8 - Hospice???????????????????????????? [Seite 560]
13.8.9 - Key references?????????????????????????????????????????? [Seite 561]
13.9 - Chapter 47 Principles of psycho-oncology?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 563]
13.9.1 - Introduction?????????????????????????????????????? [Seite 563]
13.9.2 - Clinical management???????????????????????????????????????????????????? [Seite 563]
13.9.3 - Psychosocial interventions?????????????????????????????????????????????????????????????????? [Seite 567]
13.9.4 - Burnout in oncology???????????????????????????????????????????????????? [Seite 567]
13.9.5 - References?????????????????????????????????? [Seite 568]
13.10 - Chapter 48 Principles of cancer rehabilitation medicine???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 569]
13.10.1 - Introduction?????????????????????????????????????? [Seite 569]
13.10.2 - The rehabilitation team???????????????????????????????????????????????????????????? [Seite 569]
13.10.3 - Cancer of the brain???????????????????????????????????????????????????? [Seite 569]
13.10.4 - Spinal cord dysfunction???????????????????????????????????????????????????????????? [Seite 569]
13.10.5 - Cancer of the head and neck???????????????????????????????????????????????????????????????????? [Seite 571]
13.10.6 - Cancer of the breast?????????????????????????????????????????????????????? [Seite 571]
13.10.7 - Cancer of the limbs???????????????????????????????????????????????????? [Seite 571]
13.10.8 - Conclusion?????????????????????????????????? [Seite 572]
13.10.9 - References?????????????????????????????????? [Seite 572]
13.11 - Chapter 49 Integrative oncology in cancer care?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 575]
13.11.1 - Introduction?????????????????????????????????????? [Seite 575]
13.11.2 - Definitions???????????????????????????????????? [Seite 575]
13.11.3 - Utilization???????????????????????????????????? [Seite 575]
13.11.4 - Communication???????????????????????????????????????? [Seite 576]
13.11.5 - The evidence?????????????????????????????????????? [Seite 576]
13.11.6 - Educational resources???????????????????????????????????????????????????????? [Seite 578]
13.11.7 - Integrative oncology in clinical practice???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 578]
13.11.8 - Conclusion?????????????????????????????????? [Seite 579]
13.11.9 - Key references?????????????????????????????????????????? [Seite 579]
13.12 - Chapter 50 Health services research???????????????????????????????????????????????????????????????????????????????????? [Seite 581]
13.12.1 - Introduction-what is health services research??????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 581]
13.12.2 - The significance of health services research in cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 581]
13.12.3 - Disciplines within health services research???????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 581]
13.12.4 - An overview of health services research study designs???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 582]
13.12.5 - Types of secondary data sources relevant to HSR in oncology???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 582]
13.12.6 - Statistical analyses in health services research?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 583]
13.12.7 - Different outcomes methods?????????????????????????????????????????????????????????????????? [Seite 585]
13.12.8 - Quality of care???????????????????????????????????????????? [Seite 587]
13.12.9 - HSR 2.0???????????????????????????? [Seite 588]
13.12.10 - Outcomes and endpoints?????????????????????????????????????????????????????????? [Seite 588]
13.12.11 - Comparative effectiveness research?????????????????????????????????????????????????????????????????????????????????? [Seite 590]
13.12.12 - Key references?????????????????????????????????????????? [Seite 558]
14 - Part 7 Individualized Treatment???????????????????????????????????????????????????????????????????????????? [Seite 591]
14.1 - Chapter 51 Personalized medicine in oncology drug development???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 593]
14.1.1 - Introduction?????????????????????????????????????? [Seite 593]
14.1.2 - Role of biomarkers and companion diagnostics in personalized medicine???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 593]
14.1.3 - Personalized immunotherapeutics???????????????????????????????????????????????????????????????????????????? [Seite 598]
14.1.4 - Conclusions???????????????????????????????????? [Seite 600]
14.1.5 - Key references?????????????????????????????????????????? [Seite 600]
15 - Part 8 Chemotherapy???????????????????????????????????????????????????? [Seite 603]
15.1 - Chapter 52 Preclinical and early clinical development of chemotherapeutic drugs, mechanism-based agents and biologics???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 605]
15.1.1 - Evolution of the discovery process?????????????????????????????????????????????????????????????????????????????????? [Seite 605]
15.1.2 - Special aspects developing protein-engineered compounds???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 609]
15.1.3 - Sources of compounds to evaluate against targets?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 610]
15.1.4 - Preparation of agents for clinical trials???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 610]
15.1.5 - Preparation of an IND (investigational new drug) application?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 611]
15.1.6 - Early clinical trials???????????????????????????????????????????????????????? [Seite 611]
15.1.7 - Combination of agents in Phase I trials???????????????????????????????????????????????????????????????????????????????????????????? [Seite 616]
15.1.8 - Are Phase I clinical trials therapeutic??????????????????????????????????????????????????????????????????????????????????????????????? [Seite 616]
15.1.9 - Issues regarding Phase I trials in general?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 617]
15.1.10 - Future technologies likely to impact on Phase I trials?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 618]
15.1.11 - Appendix?????????????????????????????? [Seite 618]
15.1.12 - Key references?????????????????????????????????????????? [Seite 618]
15.2 - Chapter 53 Tumor growth kinetics?????????????????????????????????????????????????????????????????????????????? [Seite 621]
15.2.1 - Introduction?????????????????????????????????????? [Seite 621]
15.2.2 - Some mysteries in cancer medicine???????????????????????????????????????????????????????????????????????????????? [Seite 621]
15.2.3 - Polygenetic etiology of cancer?????????????????????????????????????????????????????????????????????????? [Seite 621]
15.2.4 - Molecular classification versus cancer stem cell concept?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 621]
15.2.5 - Cancer as a local versus systemic disease???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 622]
15.2.6 - Gompertzian growth?????????????????????????????????????????????????? [Seite 622]
15.2.7 - The kinetics of cellular proliferation?????????????????????????????????????????????????????????????????????????????????????????? [Seite 623]
15.2.8 - Assessing growth parameters???????????????????????????????????????????????????????????????????? [Seite 623]
15.2.9 - Growth fraction, death fraction, tumor size, and therapeutic response???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 623]
15.2.10 - The kinetics of chemotherapy response???????????????????????????????????????????????????????????????????????????????????????? [Seite 624]
15.2.11 - The etiology of Gompertzian growth?????????????????????????????????????????????????????????????????????????????????? [Seite 628]
15.2.12 - The interrelationship of tumor self-seeding and tumor microenvironment?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 629]
15.2.13 - Conclusion?????????????????????????????????? [Seite 630]
15.2.14 - References?????????????????????????????????? [Seite 630]
15.3 - Chapter 54 Principles of dose, schedule, and combination therapy?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 633]
15.3.1 - Introduction?????????????????????????????????????? [Seite 633]
15.3.2 - Dose?????????????????????? [Seite 633]
15.3.3 - Factors influencing the dose effect???????????????????????????????????????????????????????????????????????????????????? [Seite 634]
15.3.4 - Schedule of drug administration???????????????????????????????????????????????????????????????????????????? [Seite 638]
15.3.5 - Combination chemotherapy?????????????????????????????????????????????????????????????? [Seite 639]
15.3.6 - Molecular biology/targeted therapy?????????????????????????????????????????????????????????????????????????????????? [Seite 642]
15.3.7 - Key references?????????????????????????????????????????? [Seite 643]
15.4 - Chapter 55 Pharmacology???????????????????????????????????????????????????????????? [Seite 645]
15.4.1 - General attributes of the drug?????????????????????????????????????????????????????????????????????????? [Seite 645]
15.4.2 - General clinical pharmacology???????????????????????????????????????????????????????????????????????? [Seite 646]
15.4.3 - Intrinsic factors???????????????????????????????????????????????? [Seite 653]
15.4.4 - Extrinsic factors???????????????????????????????????????????????? [Seite 654]
15.4.5 - General biopharmaceutics?????????????????????????????????????????????????????????????? [Seite 654]
15.4.6 - Conclusions???????????????????????????????????? [Seite 655]
15.4.7 - Acknowledgments???????????????????????????????????????????? [Seite 655]
15.4.8 - Key references?????????????????????????????????????????? [Seite 655]
15.5 - Chapter 56 Folate antagonists???????????????????????????????????????????????????????????????????????? [Seite 657]
15.5.1 - Historical overview???????????????????????????????????????????????????? [Seite 657]
15.5.2 - Mechanisms of action of MTX???????????????????????????????????????????????????????????????????? [Seite 657]
15.5.3 - Pharmacokinetics of MTX???????????????????????????????????????????????????????????? [Seite 658]
15.5.4 - Clinical application?????????????????????????????????????????????????????? [Seite 660]
15.5.5 - Current uses for MTX in the treatment of neoplastic disease???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 661]
15.5.6 - Adverse effects???????????????????????????????????????????? [Seite 662]
15.5.7 - Resistance to antifolates???????????????????????????????????????????????????????????????? [Seite 664]
15.5.8 - Strategies to overcome resistance to MTX using new (or older) antifols?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 665]
15.5.9 - Acknowledgments???????????????????????????????????????????? [Seite 666]
15.5.10 - Key references?????????????????????????????????????????? [Seite 666]
15.6 - Chapter 57 Pyrimidine and purine antimetabolites?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 669]
15.6.1 - Pyrimidine antimetabolites?????????????????????????????????????????????????????????????????? [Seite 669]
15.6.2 - Uracil antimetabolites?????????????????????????????????????????????????????????? [Seite 669]
15.6.3 - Cytosine antimetabolites?????????????????????????????????????????????????????????????? [Seite 671]
15.6.4 - Purine antimetabolites?????????????????????????????????????????????????????????? [Seite 675]
15.6.5 - Guanine antimetabolites???????????????????????????????????????????????????????????? [Seite 675]
15.6.6 - Adenosine antimetabolites???????????????????????????????????????????????????????????????? [Seite 677]
15.6.7 - References?????????????????????????????????? [Seite 680]
15.7 - Chapter 58 Alkylating agents and platinum antitumor compounds???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 681]
15.7.1 - Introduction?????????????????????????????????????? [Seite 681]
15.7.2 - General mechanisms of cytotoxicity?????????????????????????????????????????????????????????????????????????????????? [Seite 681]
15.7.3 - Alkylating agents???????????????????????????????????????????????? [Seite 682]
15.7.4 - Platinum antitumor compounds?????????????????????????????????????????????????????????????????????? [Seite 692]
15.7.5 - Acknowledgments???????????????????????????????????????????? [Seite 695]
15.7.6 - Key references?????????????????????????????????????????? [Seite 695]
15.8 - Chapter 59 DNA topoisomerase targeting drugs?????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 697]
15.8.1 - Introduction?????????????????????????????????????? [Seite 697]
15.8.2 - Topoisomerase biology???????????????????????????????????????????????????????? [Seite 697]
15.8.3 - Mechanisms of action?????????????????????????????????????????????????????? [Seite 697]
15.8.4 - Topoisomerase I inhibitors?????????????????????????????????????????????????????????????????? [Seite 700]
15.8.5 - Top2 inhibitors???????????????????????????????????????????? [Seite 704]
15.8.6 - Pharmacogenomics?????????????????????????????????????????????? [Seite 707]
15.8.7 - Perspectives?????????????????????????????????????? [Seite 709]
15.8.8 - References?????????????????????????????????? [Seite 709]
15.9 - Chapter 60 Agents targeting microtubules and mitotic processes?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 711]
15.9.1 - Introduction?????????????????????????????????????? [Seite 711]
15.9.2 - Microtubules as strategic targets against cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 711]
15.9.3 - Microtubule structure and dynamics?????????????????????????????????????????????????????????????????????????????????? [Seite 712]
15.9.4 - Treadmilling and dynamic instability?????????????????????????????????????????????????????????????????????????????????????? [Seite 712]
15.9.5 - Microtubules and mitosis?????????????????????????????????????????????????????????????? [Seite 712]
15.9.6 - Regulating microtubule dynamics and functional diversity?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 713]
15.9.7 - Vinca alkaloids: Introduction and indications???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 713]
15.9.8 - Mechanism of action???????????????????????????????????????????????????? [Seite 715]
15.9.9 - Mechanisms of resistance?????????????????????????????????????????????????????????????? [Seite 716]
15.9.10 - Pharmacology?????????????????????????????????????? [Seite 717]
15.9.11 - Drug interactions???????????????????????????????????????????????? [Seite 719]
15.9.12 - Toxicity?????????????????????????????? [Seite 719]
15.9.13 - Administration, dose, and schedule?????????????????????????????????????????????????????????????????????????????????? [Seite 721]
15.9.14 - Taxanes: Introduction and indications???????????????????????????????????????????????????????????????????????????????????????? [Seite 722]
15.9.15 - Clinical indications?????????????????????????????????????????????????????? [Seite 722]
15.9.16 - Mechanisms of action?????????????????????????????????????????????????????? [Seite 724]
15.9.17 - Mechanisms of resistance?????????????????????????????????????????????????????????????? [Seite 725]
15.9.18 - Clinical pharmacology???????????????????????????????????????????????????????? [Seite 727]
15.9.19 - Drug interactions???????????????????????????????????????????????? [Seite 729]
15.9.20 - Toxicity?????????????????????????????? [Seite 730]
15.9.21 - Administration, dose, and schedule?????????????????????????????????????????????????????????????????????????????????? [Seite 733]
15.9.22 - Other natural products that enhance tubulin polymerization?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 735]
15.9.23 - Ixabepilone and the epothilones???????????????????????????????????????????????????????????????????????????? [Seite 735]
15.9.24 - Clinical indications?????????????????????????????????????????????????????? [Seite 736]
15.9.25 - Mechanism of action???????????????????????????????????????????????????? [Seite 736]
15.9.26 - Mechanisms of resistance?????????????????????????????????????????????????????????????? [Seite 736]
15.9.27 - Clinical pharmacology???????????????????????????????????????????????????????? [Seite 736]
15.9.28 - Drug interactions???????????????????????????????????????????????? [Seite 737]
15.9.29 - Toxicity?????????????????????????????? [Seite 737]
15.9.30 - Administration, dose, and schedule?????????????????????????????????????????????????????????????????????????????????? [Seite 738]
15.9.31 - Eribulin mesylate and natural products that enhance tubulin depolymerization?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 739]
15.9.32 - Eribulin mesylate???????????????????????????????????????????????? [Seite 739]
15.9.33 - Clinical indications?????????????????????????????????????????????????????? [Seite 739]
15.9.34 - Mechanism of action???????????????????????????????????????????????????? [Seite 739]
15.9.35 - Mechanism of resistance???????????????????????????????????????????????????????????? [Seite 740]
15.9.36 - Clinical pharmacology???????????????????????????????????????????????????????? [Seite 740]
15.9.37 - Drug interactions???????????????????????????????????????????????? [Seite 740]
15.9.38 - Toxicity?????????????????????????????? [Seite 740]
15.9.39 - Administration, dose, and schedule?????????????????????????????????????????????????????????????????????????????????? [Seite 740]
15.9.40 - Targeting mitotic motor proteins and kinases?????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 741]
15.9.41 - Antibody-drug conjugates carrying antimicrotubule drug payloads???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 742]
15.9.42 - Key references?????????????????????????????????????????? [Seite 744]
15.10 - Chapter 61 Endocrine therapy for hormone receptor-positive breast cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 745]
15.10.1 - Biology of progestin production and action?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 745]
15.10.2 - Biology of estrogen production and action???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 747]
15.10.3 - Selective estrogen receptor modulators and antiestrogens?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 749]
15.10.4 - Aromatase inhibitors?????????????????????????????????????????????????????? [Seite 754]
15.10.5 - Resistance to endocrine therapy???????????????????????????????????????????????????????????????????????????? [Seite 761]
15.10.6 - GnRH analogues and ovarian function preservation?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 763]
15.10.7 - Conclusion?????????????????????????????????? [Seite 763]
15.10.8 - Key references?????????????????????????????????????????? [Seite 764]
15.11 - Chapter 62 Drug resistance and its clinical circumvention???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 765]
15.11.1 - General mechanisms of resistance to single agents???????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 765]
15.11.2 - General mechanisms of resistance to multiple agents???????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 766]
15.11.3 - Potential clinical application of strategies to avert or overcome drug resistance???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 769]
15.11.4 - Conclusion and future directions?????????????????????????????????????????????????????????????????????????????? [Seite 770]
15.11.5 - References?????????????????????????????????? [Seite 770]
16 - Part 9 Biological and Gene Therapy?????????????????????????????????????????????????????????????????????????????????? [Seite 773]
16.1 - Chapter 63 Cytokines, interferons, and hematopoietic growth factors???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 775]
16.1.1 - Interleukins?????????????????????????????????????? [Seite 775]
16.1.2 - Interferons???????????????????????????????????? [Seite 783]
16.1.3 - Hematopoiesis and the role of growth factors?????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 785]
16.1.4 - Future perspectives???????????????????????????????????????????????????? [Seite 788]
16.1.5 - Acknowledgment?????????????????????????????????????????? [Seite 788]
16.1.6 - Key references?????????????????????????????????????????? [Seite 788]
16.2 - Chapter 64 Monoclonal serotherapy???????????????????????????????????????????????????????????????????????????????? [Seite 789]
16.2.1 - Introduction?????????????????????????????????????? [Seite 789]
16.2.2 - Serotherapy for leukemia and lymphoma with unmodified monoclonal antibodies???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 789]
16.2.3 - Serotherapy for solid tumors with unmodified monoclonal antibodies?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 792]
16.2.4 - Immune checkpoint inhibitors?????????????????????????????????????????????????????????????????????? [Seite 798]
16.2.5 - Barriers to treatment with unmodified monoclonal antibodies???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 799]
16.2.6 - Serotherapy with monoclonal antibody drug conjugates (ADCs)???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 800]
16.2.7 - Radioimmunotherapy of cancer?????????????????????????????????????????????????????????????????????? [Seite 801]
16.2.8 - Therapy with targeted toxins?????????????????????????????????????????????????????????????????????? [Seite 804]
16.2.9 - Key references?????????????????????????????????????????? [Seite 806]
16.3 - Chapter 65 Vaccines and immunostimulants?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 809]
16.3.1 - Targets for vaccine therapy???????????????????????????????????????????????????????????????????? [Seite 809]
16.3.2 - Types of vaccines???????????????????????????????????????????????? [Seite 810]
16.3.3 - Non-specific immune stimulants?????????????????????????????????????????????????????????????????????????? [Seite 812]
16.3.4 - Vaccine clinical trials???????????????????????????????????????????????????????????? [Seite 813]
16.3.5 - Combination therapies???????????????????????????????????????????????????????? [Seite 817]
16.3.6 - Mechanisms involved in vaccine activity???????????????????????????????????????????????????????????????????????????????????????????? [Seite 821]
16.3.7 - Immune monitoring???????????????????????????????????????????????? [Seite 822]
16.3.8 - Paradigm shifts???????????????????????????????????????????? [Seite 823]
16.3.9 - Acknowledgments???????????????????????????????????????????? [Seite 823]
16.3.10 - Key references?????????????????????????????????????????? [Seite 823]
16.4 - Chapter 66 Cell-based cancer immunotherapy?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 825]
16.4.1 - Introduction?????????????????????????????????????? [Seite 825]
16.4.2 - Conclusion?????????????????????????????????? [Seite 831]
16.4.3 - Acknowledgments???????????????????????????????????????????? [Seite 832]
16.4.4 - Key references?????????????????????????????????????????? [Seite 832]
16.5 - Chapter 67 Cancer immunotherapy???????????????????????????????????????????????????????????????????????????? [Seite 833]
16.5.1 - Immunosurveillance?????????????????????????????????????????????????? [Seite 833]
16.5.2 - Immunoediting???????????????????????????????????????? [Seite 833]
16.5.3 - Immune tolerance?????????????????????????????????????????????? [Seite 834]
16.5.4 - Early failures-lessons learnt???????????????????????????????????????????????????????????????????????? [Seite 834]
16.5.5 - Mediators of immune escape?????????????????????????????????????????????????????????????????? [Seite 835]
16.5.6 - Noncell-autonomous suppression?????????????????????????????????????????????????????????????????????????? [Seite 835]
16.5.7 - Moving toward clinically effective immunotherapies?????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 837]
16.5.8 - Adoptive cell therapy and the development of personalized immunotherapies???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 837]
16.5.9 - Generation of cellular therapy products???????????????????????????????????????????????????????????????????????????????????????????? [Seite 838]
16.5.10 - The role of lymphodepletion???????????????????????????????????????????????????????????????????? [Seite 839]
16.5.11 - Current position of adoptive T cell transfer?????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 839]
16.5.12 - Promoting DC function???????????????????????????????????????????????????????? [Seite 839]
16.5.13 - Directly promoting T cell function?????????????????????????????????????????????????????????????????????????????????? [Seite 840]
16.5.14 - Stimulatory antibodies to 4-1BB (CD137), OX40 (CD134), and GITR-accentuating the positive??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 840]
16.5.15 - Stimulation through checkpoint blockade of CTLA-4 (CD152), PD-1 (CD279), PD-L1 (CD274)-eliminating the negative???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 842]
16.5.16 - Targeting Treg suppressive capacity???????????????????????????????????????????????????????????????????????????????????? [Seite 844]
16.5.17 - Cytokines-intercellular mediators of immunity???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 845]
16.5.18 - Combinatorial immunotherapeutics?????????????????????????????????????????????????????????????????????????????? [Seite 845]
16.5.19 - Immunotherapy agents elicit different toxicities?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 846]
16.5.20 - Paradigm shift-from immune adjuvants to immunosupportive therapies????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 846]
16.5.21 - Key references?????????????????????????????????????????? [Seite 846]
16.6 - Chapter 68 Cancer gene therapy?????????????????????????????????????????????????????????????????????????? [Seite 849]
16.6.1 - Introduction?????????????????????????????????????? [Seite 849]
16.6.2 - Delivery of genetic material to target cells?????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 849]
16.6.3 - Targets of gene therapy???????????????????????????????????????????????????????????? [Seite 851]
16.6.4 - Safety?????????????????????????? [Seite 854]
16.6.5 - Conclusion: How will cancer gene therapy enter clinical practice????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 854]
16.6.6 - Key references?????????????????????????????????????????? [Seite 854]
16.7 - Chapter 69 Cancer nanotechnology?????????????????????????????????????????????????????????????????????????????? [Seite 857]
16.7.1 - Introduction?????????????????????????????????????? [Seite 857]
16.7.2 - Clinical stage cancer nanotechnologies?????????????????????????????????????????????????????????????????????????????????????????? [Seite 857]
16.7.3 - Recent advances in cancer nanotechnologies?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 861]
16.7.4 - Acknowledgments???????????????????????????????????????????? [Seite 861]
16.7.5 - Key references?????????????????????????????????????????? [Seite 861]
16.8 - Chapter 70 Hematopoietic cell transplantation???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 863]
16.8.1 - Methods of transplantation?????????????????????????????????????????????????????????????????? [Seite 863]
16.8.2 - Hematopoietic transplantation as treatment for malignancies???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 863]
16.8.3 - Donor selection???????????????????????????????????????????? [Seite 864]
16.8.4 - Selection of autologous or allogeneic transplantation???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 865]
16.8.5 - Pretransplant therapy???????????????????????????????????????????????????????? [Seite 866]
16.8.6 - Complications of hematopoietic transplantation?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 867]
16.8.7 - Indications for hematopoietic transplantation???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 869]
16.8.8 - Future directions???????????????????????????????????????????????? [Seite 872]
16.8.9 - Key references?????????????????????????????????????????? [Seite 872]
17 - Part 10 Special Populations???????????????????????????????????????????????????????????????????? [Seite 875]
17.1 - Chapter 71 Principles of pediatric oncology???????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 877]
17.1.1 - Introduction and epidemiology???????????????????????????????????????????????????????????????????????? [Seite 877]
17.1.2 - Renal tumors?????????????????????????????????????? [Seite 882]
17.1.3 - Neuroblastoma???????????????????????????????????????? [Seite 884]
17.1.4 - Pediatric bone tumors???????????????????????????????????????????????????????? [Seite 885]
17.1.5 - Central nervous system tumors???????????????????????????????????????????????????????????????????????? [Seite 888]
17.1.6 - Less-frequently encountered tumors?????????????????????????????????????????????????????????????????????????????????? [Seite 890]
17.1.7 - Late effects and quality of survivorship?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 892]
17.1.8 - Acknowledgments???????????????????????????????????????????? [Seite 894]
17.1.9 - Key references?????????????????????????????????????????? [Seite 894]
17.2 - Chapter 72 Cancer and pregnancy???????????????????????????????????????????????????????????????????????????? [Seite 897]
17.2.1 - Cancer and pregnancy epidemiology???????????????????????????????????????????????????????????????????????????????? [Seite 897]
17.2.2 - Diagnosis and staging???????????????????????????????????????????????????????? [Seite 897]
17.2.3 - Cancer treatment during pregnancy???????????????????????????????????????????????????????????????????????????????? [Seite 898]
17.2.4 - Surgery???????????????????????????? [Seite 898]
17.2.5 - Radiation???????????????????????????????? [Seite 898]
17.2.6 - Systemic therapy?????????????????????????????????????????????? [Seite 898]
17.2.7 - Specific cancers?????????????????????????????????????????????? [Seite 900]
17.2.8 - Acute and chronic leukemia?????????????????????????????????????????????????????????????????? [Seite 903]
17.2.9 - Transplacental malignancy and placental metastasis?????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 904]
17.2.10 - Conclusion?????????????????????????????????? [Seite 904]
17.2.11 - Key references?????????????????????????????????????????? [Seite 904]
17.3 - Chapter 73 Cancer and aging???????????????????????????????????????????????????????????????????? [Seite 907]
17.3.1 - Life expectancy and aging???????????????????????????????????????????????????????????????? [Seite 907]
17.3.2 - The biology of cancer and aging???????????????????????????????????????????????????????????????????????????? [Seite 907]
17.3.3 - Physiologic changes with aging?????????????????????????????????????????????????????????????????????????? [Seite 908]
17.3.4 - The frail older patient???????????????????????????????????????????????????????????? [Seite 908]
17.3.5 - Evaluation of the older patient: geriatric assessment???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 909]
17.3.6 - Comorbid medical conditions???????????????????????????????????????????????????????????????????? [Seite 909]
17.3.7 - Comprehensive geriatric assessment?????????????????????????????????????????????????????????????????????????????????? [Seite 911]
17.3.8 - Knowledge about older cancer patients: underrepresentation on clinical trials???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 912]
17.3.9 - Understanding barriers to clinical trial enrollment???????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 912]
17.3.10 - Cancer screening in the elderly???????????????????????????????????????????????????????????????????????????? [Seite 912]
17.3.11 - Treatment tolerance of the older patient?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 913]
17.3.12 - Conclusions???????????????????????????????????? [Seite 914]
17.3.13 - Key references?????????????????????????????????????????? [Seite 914]
17.4 - Chapter 74 Disparities in cancer care???????????????????????????????????????????????????????????????????????????????????????? [Seite 915]
17.4.1 - Introduction?????????????????????????????????????? [Seite 915]
17.4.2 - The birth of a discipline???????????????????????????????????????????????????????????????? [Seite 915]
17.4.3 - Defining health disparities???????????????????????????????????????????????????????????????????? [Seite 915]
17.4.4 - Factors measured?????????????????????????????????????????????? [Seite 916]
17.4.5 - Population categorization???????????????????????????????????????????????????????????????? [Seite 916]
17.4.6 - Relationships among population categories???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 917]
17.4.7 - Disparities in treatment patterns???????????????????????????????????????????????????????????????????????????????? [Seite 918]
17.4.8 - Disparities in quality of care lead to disparities in prognosis and treatment???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 918]
17.4.9 - Genetic expression-race, ancestry, ethnicity, and culture???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 918]
17.4.10 - Population and genetic differences?????????????????????????????????????????????????????????????????????????????????? [Seite 919]
17.4.11 - Pharmacogenomics?????????????????????????????????????????????? [Seite 919]
17.4.12 - US Government rules on minority inclusion in clinical trials?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 920]
17.4.13 - References?????????????????????????????????? [Seite 920]
17.5 - Chapter 75 Neoplasms in acquired immunodeficiency syndrome?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 923]
17.5.1 - Epidemiology?????????????????????????????????????? [Seite 923]
17.5.2 - Kaposi sarcoma (KS)???????????????????????????????????????????????????? [Seite 925]
17.5.3 - Non-Hodgkin lymphoma (NHL)?????????????????????????????????????????????????????????????????? [Seite 931]
17.5.4 - Hodgkin lymphoma (HL)???????????????????????????????????????????????????????? [Seite 938]
17.5.5 - Squamous cell neoplasia???????????????????????????????????????????????????????????? [Seite 938]
17.5.6 - Other non-AIDS defining cancers???????????????????????????????????????????????????????????????????????????? [Seite 940]
17.5.7 - Key references?????????????????????????????????????????? [Seite 940]
17.6 - Chapter 76 Cancer survivorship: new challenge in cancer medicine?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 941]
17.6.1 - Introduction?????????????????????????????????????? [Seite 941]
17.6.2 - Cancer survivorship: a brief history?????????????????????????????????????????????????????????????????????????????????????? [Seite 941]
17.6.3 - Magnitude of the problem?????????????????????????????????????????????????????????????? [Seite 941]
17.6.4 - Providing survivorship care???????????????????????????????????????????????????????????????????? [Seite 944]
17.6.5 - Families and informal caregivers?????????????????????????????????????????????????????????????????????????????? [Seite 946]
17.6.6 - Conclusion?????????????????????????????????? [Seite 946]
17.6.7 - Key references?????????????????????????????????????????? [Seite 947]
18 - Part 11 Disease Sites???????????????????????????????????????????????????????? [Seite 949]
18.1 - Chapter 77 Primary and metastatic neoplasms of the brain in adults?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 951]
18.1.1 - Introduction?????????????????????????????????????? [Seite 951]
18.1.2 - Epidemiology?????????????????????????????????????? [Seite 951]
18.1.3 - Glioblastoma and anaplastic astrocytoma???????????????????????????????????????????????????????????????????????????????????????????? [Seite 958]
18.1.4 - Anaplastic gliomas?????????????????????????????????????????????????? [Seite 958]
18.1.5 - Low-grade gliomas and oligodendrogliomas?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 958]
18.1.6 - Ependymoma?????????????????????????????????? [Seite 959]
18.1.7 - Primary central nervous system lymphoma???????????????????????????????????????????????????????????????????????????????????????????? [Seite 960]
18.1.8 - Meningioma?????????????????????????????????? [Seite 961]
18.1.9 - Brain metastasis?????????????????????????????????????????????? [Seite 962]
18.1.10 - Pathophysiology of the metastatic process???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 962]
18.1.11 - Key references?????????????????????????????????????????? [Seite 965]
18.2 - Chapter 78 Neoplasms of the eye???????????????????????????????????????????????????????????????????????????? [Seite 967]
18.2.1 - Introduction?????????????????????????????????????? [Seite 967]
18.2.2 - Pediatric ophthalmic oncology: ocular diseases?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 967]
18.2.3 - Pediatric ophthalmic oncology: orbital diseases???????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 973]
18.2.4 - Adult ophthalmic oncology: ocular diseases?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 973]
18.2.5 - Adult ophthalmic oncology: orbital diseases???????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 977]
18.2.6 - References?????????????????????????????????? [Seite 978]
18.3 - Chapter 79 Neoplasms of the endocrine glands: pituitary neoplasms???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 981]
18.3.1 - Prolactin-secreting pituitary adenomas?????????????????????????????????????????????????????????????????????????????????????????? [Seite 983]
18.3.2 - Growth hormone-secreting pituitary adenomas???????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 984]
18.3.3 - Adrenocorticotrophic hormone-secreting adenomas???????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 986]
18.3.4 - Gonadotropin-secreting and nonsecretory pituitary adenomas?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 987]
18.3.5 - TSH-secreting pituitary adenomas?????????????????????????????????????????????????????????????????????????????? [Seite 988]
18.3.6 - Conclusion?????????????????????????????????? [Seite 988]
18.3.7 - Key references?????????????????????????????????????????? [Seite 989]
18.4 - Chapter 80 Neoplasms of the thyroid???????????????????????????????????????????????????????????????????????????????????? [Seite 991]
18.4.1 - Historical perspective?????????????????????????????????????????????????????????? [Seite 991]
18.4.2 - Incidence and epidemiology-local and worldwide?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 991]
18.4.3 - Risk factors-genetic, behavioral, environmental???????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 991]
18.4.4 - Prevention?????????????????????????????????? [Seite 991]
18.4.5 - Pathology???????????????????????????????? [Seite 991]
18.4.6 - Pathogenesis and natural history?????????????????????????????????????????????????????????????????????????????? [Seite 992]
18.4.7 - Screening???????????????????????????????? [Seite 992]
18.4.8 - Diagnosis???????????????????????????????? [Seite 993]
18.4.9 - TNM staging, classification???????????????????????????????????????????????????????????????????? [Seite 993]
18.4.10 - Prognostic factors?????????????????????????????????????????????????? [Seite 993]
18.4.11 - Multidisciplinary care?????????????????????????????????????????????????????????? [Seite 994]
18.4.12 - Key references?????????????????????????????????????????? [Seite 996]
18.5 - Chapter 81 Neoplasms of the adrenal cortex?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 999]
18.5.1 - Introduction?????????????????????????????????????? [Seite 999]
18.5.2 - General???????????????????????????? [Seite 999]
18.5.3 - Evaluation and work-up?????????????????????????????????????????????????????????? [Seite 999]
18.5.4 - The role of a biopsy?????????????????????????????????????????????????????? [Seite 999]
18.5.5 - Pathology???????????????????????????????? [Seite 999]
18.5.6 - Management of ACC???????????????????????????????????????????????? [Seite 999]
18.5.7 - Conclusion?????????????????????????????????? [Seite 1000]
18.5.8 - References?????????????????????????????????? [Seite 1001]
18.6 - Chapter 82 Tumors of the diffuse neuroendocrine and gastroenteropancreatic system???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1003]
18.6.1 - Epidemiology?????????????????????????????????????? [Seite 1003]
18.6.2 - The diffuse endocrine system?????????????????????????????????????????????????????????????????????? [Seite 1004]
18.6.3 - Histology and staging of neuroendocrine tumors?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1005]
18.6.4 - Clinical features of tumors of the DES?????????????????????????????????????????????????????????????????????????????????????????? [Seite 1005]
18.6.5 - Gastrointestinal neuroendocrine tumors (GI-NETs)?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1005]
18.6.6 - Pancreatic net (PNET) (islet-cell tumors)???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1006]
18.6.7 - Therapy for GEP-NET???????????????????????????????????????????????????? [Seite 1008]
18.6.8 - MEN syndromes???????????????????????????????????????? [Seite 1009]
18.6.9 - MEN-2 syndromes???????????????????????????????????????????? [Seite 1010]
18.6.10 - Pheochromocytoma?????????????????????????????????????????????? [Seite 1011]
18.6.11 - Key references?????????????????????????????????????????? [Seite 1011]
18.7 - Chapter 83 Neoplasms of the head and neck???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1013]
18.7.1 - Introduction?????????????????????????????????????? [Seite 1013]
18.7.2 - Descriptive epidemiology?????????????????????????????????????????????????????????????? [Seite 1013]
18.7.3 - Pathologic assessment and biology???????????????????????????????????????????????????????????????????????????????? [Seite 1016]
18.7.4 - Anatomy???????????????????????????? [Seite 1016]
18.7.5 - Diagnosis and staging???????????????????????????????????????????????????????? [Seite 1018]
18.7.6 - General principles of treatment???????????????????????????????????????????????????????????????????????????? [Seite 1019]
18.7.7 - Oral premalignancy?????????????????????????????????????????????????? [Seite 1020]
18.7.8 - Overview of natural history and treatment by site???????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1020]
18.7.9 - Radiation therapy???????????????????????????????????????????????? [Seite 1035]
18.7.10 - Systemic therapy?????????????????????????????????????????????? [Seite 1038]
18.7.11 - Key references?????????????????????????????????????????? [Seite 1041]
18.8 - Chapter 84 Cancer of the lung???????????????????????????????????????????????????????????????????????? [Seite 1043]
18.8.1 - Etiology and epidemiology???????????????????????????????????????????????????????????????? [Seite 1043]
18.8.2 - Molecular pathogenesis?????????????????????????????????????????????????????????? [Seite 1044]
18.8.3 - Molecular abnormalities in premalignancy?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1044]
18.8.4 - Pathology of lung cancer?????????????????????????????????????????????????????????????? [Seite 1044]
18.8.5 - Clinical manifestations???????????????????????????????????????????????????????????? [Seite 1048]
18.8.6 - Diagnostic and staging techniques???????????????????????????????????????????????????????????????????????????????? [Seite 1050]
18.8.7 - Therapy for NSCLC???????????????????????????????????????????????? [Seite 1054]
18.8.8 - Therapy for SCLC?????????????????????????????????????????????? [Seite 1062]
18.8.9 - Conclusions and future prospects?????????????????????????????????????????????????????????????????????????????? [Seite 1066]
18.8.10 - Key references?????????????????????????????????????????? [Seite 1067]
18.9 - Chapter 85 Malignant pleural mesothelioma???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1069]
18.9.1 - Incidence and epidemiology?????????????????????????????????????????????????????????????????? [Seite 1069]
18.9.2 - Diagnosing and staging the patient with possible mesothelioma???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1071]
18.9.3 - Surgical diagnosis and staging in mesothelioma?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1073]
18.9.4 - Treatment???????????????????????????????? [Seite 1073]
18.9.5 - Conclusion?????????????????????????????????? [Seite 1081]
18.9.6 - Key references?????????????????????????????????????????? [Seite 1081]
18.10 - Chapter 86 Thymomas and thymic tumors???????????????????????????????????????????????????????????????????????????????????????? [Seite 1083]
18.10.1 - Introduction?????????????????????????????????????? [Seite 1083]
18.10.2 - Incidence and epidemiology?????????????????????????????????????????????????????????????????? [Seite 1083]
18.10.3 - Anatomic pathogenesis???????????????????????????????????????????????????????? [Seite 1084]
18.10.4 - Pathology of thymic epithelial neoplasms?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1084]
18.10.5 - Staging systems for thymomas?????????????????????????????????????????????????????????????????????? [Seite 1086]
18.10.6 - TNM staging project-ITMIG/IASLC???????????????????????????????????????????????????????????????????????????? [Seite 1088]
18.10.7 - Clinical features of thymomas???????????????????????????????????????????????????????????????????????? [Seite 1089]
18.10.8 - Therapy???????????????????????????? [Seite 1090]
18.10.9 - Conclusion?????????????????????????????????? [Seite 1092]
18.10.10 - Key references?????????????????????????????????????????? [Seite 1092]
18.11 - Chapter 87 Tumors of the heart and great vessels?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1095]
18.11.1 - Introduction?????????????????????????????????????? [Seite 1095]
18.11.2 - Clinical features???????????????????????????????????????????????? [Seite 1095]
18.11.3 - Diagnostic evaluation???????????????????????????????????????????????????????? [Seite 1095]
18.11.4 - Cardiac tumors?????????????????????????????????????????? [Seite 1096]
18.11.5 - Tumors of the great vessels???????????????????????????????????????????????????????????????????? [Seite 1098]
18.11.6 - Key references?????????????????????????????????????????? [Seite 1098]
18.12 - Chapter 88 Primary germ cell tumors of the thorax???????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1101]
18.12.1 - Benign teratomas of the mediastinum???????????????????????????????????????????????????????????????????????????????????? [Seite 1101]
18.12.2 - Malignant GCT???????????????????????????????????????? [Seite 1101]
18.12.3 - Pretreatment evaluation and staging???????????????????????????????????????????????????????????????????????????????????? [Seite 1102]
18.12.4 - Treatment of seminoma???????????????????????????????????????????????????????? [Seite 1102]
18.12.5 - Treatment of nonseminomatous GCT?????????????????????????????????????????????????????????????????????????????? [Seite 1103]
18.12.6 - Key references?????????????????????????????????????????? [Seite 1104]
18.13 - Chapter 89 Neoplasms of the esophagus???????????????????????????????????????????????????????????????????????????????????????? [Seite 1107]
18.13.1 - Historical perspectives???????????????????????????????????????????????????????????? [Seite 1107]
18.13.2 - Anatomy and histology???????????????????????????????????????????????????????? [Seite 1107]
18.13.3 - Etiology?????????????????????????????? [Seite 1107]
18.13.4 - Epidemiology?????????????????????????????????????? [Seite 1108]
18.13.5 - Treatment overview?????????????????????????????????????????????????? [Seite 1109]
18.13.6 - Diagnosis???????????????????????????????? [Seite 1109]
18.13.7 - Pretreatment assessment???????????????????????????????????????????????????????????? [Seite 1109]
18.13.8 - Staging evaluation?????????????????????????????????????????????????? [Seite 1110]
18.13.9 - Presentation?????????????????????????????????????? [Seite 1110]
18.13.10 - Therapy???????????????????????????? [Seite 1113]
18.13.11 - Palliative therapy of esophageal obstruction?????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1121]
18.13.12 - Key references?????????????????????????????????????????? [Seite 1121]
18.14 - Chapter 90 Carcinoma of the stomach???????????????????????????????????????????????????????????????????????????????????? [Seite 1123]
18.14.1 - Incidence and epidemiology?????????????????????????????????????????????????????????????????? [Seite 1123]
18.14.2 - Risk factors?????????????????????????????????????? [Seite 1123]
18.14.3 - Pathology???????????????????????????????? [Seite 1124]
18.14.4 - Pathogenesis and natural history?????????????????????????????????????????????????????????????????????????????? [Seite 1124]
18.14.5 - Screening???????????????????????????????? [Seite 1125]
18.14.6 - Diagnosis???????????????????????????????? [Seite 1126]
18.14.7 - TNM stage classification?????????????????????????????????????????????????????????????? [Seite 1126]
18.14.8 - Multidisciplinary care?????????????????????????????????????????????????????????? [Seite 1126]
18.14.9 - Unmet needs and future directions???????????????????????????????????????????????????????????????????????????????? [Seite 1132]
18.14.10 - Conclusions???????????????????????????????????? [Seite 1132]
18.14.11 - Key references?????????????????????????????????????????? [Seite 1132]
18.15 - Chapter 91 Primary neoplasms of the liver???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1135]
18.15.1 - Hepatocellular carcinoma?????????????????????????????????????????????????????????????? [Seite 1135]
18.15.2 - Intrahepatic cholangiocarcinoma???????????????????????????????????????????????????????????????????????????? [Seite 1143]
18.15.3 - Hepatic angiosarcoma?????????????????????????????????????????????????????? [Seite 1144]
18.15.4 - Epithelioid hemangioendothelioma?????????????????????????????????????????????????????????????????????????????? [Seite 1145]
18.15.5 - Key references?????????????????????????????????????????? [Seite 1145]
18.16 - Chapter 92 Gallbladder and bile duct cancer???????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1147]
18.16.1 - Gallbladder cancer?????????????????????????????????????????????????? [Seite 1147]
18.16.2 - Bile duct cancer?????????????????????????????????????????????? [Seite 1152]
18.16.3 - Hilar bile duct cholangiocarcinoma?????????????????????????????????????????????????????????????????????????????????? [Seite 1156]
18.16.4 - Key references?????????????????????????????????????????? [Seite 1159]
18.17 - Chapter 93 Neoplasms of the exocrine pancreas???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1161]
18.17.1 - Introduction?????????????????????????????????????? [Seite 1161]
18.17.2 - Epidemiology?????????????????????????????????????? [Seite 1161]
18.17.3 - Etiologic factors???????????????????????????????????????????????? [Seite 1161]
18.17.4 - Prevention of pancreatic cancer???????????????????????????????????????????????????????????????????????????? [Seite 1164]
18.17.5 - Pathology???????????????????????????????? [Seite 1164]
18.17.6 - Diagnostic evaluation???????????????????????????????????????????????????????? [Seite 1167]
18.17.7 - Treatment of localized, potentially resectable disease?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1169]
18.17.8 - Adjuvant (postoperative) therapy?????????????????????????????????????????????????????????????????????????????? [Seite 1172]
18.17.9 - Preoperative (neoadjuvant) therapy?????????????????????????????????????????????????????????????????????????????????? [Seite 1173]
18.17.10 - Locally advanced pancreatic cancer?????????????????????????????????????????????????????????????????????????????????? [Seite 1174]
18.17.11 - Novel approaches to chemoradiation?????????????????????????????????????????????????????????????????????????????????? [Seite 1176]
18.17.12 - The role of systemic therapy in pancreatic cancer???????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1176]
18.17.13 - Approach to the patient with metastatic disease???????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1178]
18.17.14 - Future directions???????????????????????????????????????????????? [Seite 1179]
18.17.15 - Key references?????????????????????????????????????????? [Seite 1180]
18.18 - Chapter 94 Neoplasms of the small intestine, vermiform appendix, and peritoneum, and carcinoma of the colon and rectum?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1183]
18.18.1 - Tumors of the small intestine???????????????????????????????????????????????????????????????????????? [Seite 1183]
18.18.2 - Tumors of the appendix?????????????????????????????????????????????????????????? [Seite 1189]
18.18.3 - Carcinoma of the colon and rectum???????????????????????????????????????????????????????????????????????????????? [Seite 1191]
18.18.4 - Key references?????????????????????????????????????????? [Seite 1207]
18.19 - Chapter 95 Neoplasms of the anus?????????????????????????????????????????????????????????????????????????????? [Seite 1209]
18.19.1 - Gross anatomy???????????????????????????????????????? [Seite 1209]
18.19.2 - Epidemiology?????????????????????????????????????? [Seite 1209]
18.19.3 - Etiology?????????????????????????????? [Seite 1209]
18.19.4 - Pathology???????????????????????????????? [Seite 1210]
18.19.5 - Natural history???????????????????????????????????????????? [Seite 1210]
18.19.6 - Diagnosis???????????????????????????????? [Seite 1210]
18.19.7 - Staging???????????????????????????? [Seite 1211]
18.19.8 - Prognostic factors?????????????????????????????????????????????????? [Seite 1211]
18.19.9 - Treatment for primary disease???????????????????????????????????????????????????????????????????????? [Seite 1212]
18.19.10 - Treatment of the HIV-positive patient???????????????????????????????????????????????????????????????????????????????????????? [Seite 1216]
18.19.11 - Treatment of anal margin cancer???????????????????????????????????????????????????????????????????????????? [Seite 1216]
18.19.12 - Follow-up after treatment???????????????????????????????????????????????????????????????? [Seite 1216]
18.19.13 - Management of inguinal nodes?????????????????????????????????????????????????????????????????????? [Seite 1216]
18.19.14 - Residual or recurrent cancer?????????????????????????????????????????????????????????????????????? [Seite 1217]
18.19.15 - Treatment of metastatic disease???????????????????????????????????????????????????????????????????????????? [Seite 1217]
18.19.16 - Other histologies???????????????????????????????????????????????? [Seite 1217]
18.19.17 - Key references?????????????????????????????????????????? [Seite 1217]
18.20 - Chapter 96 Renal cell carcinoma???????????????????????????????????????????????????????????????????????????? [Seite 1219]
18.20.1 - Introduction?????????????????????????????????????? [Seite 1219]
18.20.2 - Epidemiology?????????????????????????????????????? [Seite 1219]
18.20.3 - Clinical presentation???????????????????????????????????????????????????????? [Seite 1219]
18.20.4 - Pathology???????????????????????????????? [Seite 1219]
18.20.5 - Prognostic features???????????????????????????????????????????????????? [Seite 1220]
18.20.6 - Treatment of localized RCC?????????????????????????????????????????????????????????????????? [Seite 1220]
18.20.7 - Metastatic disease?????????????????????????????????????????????????? [Seite 1221]
18.20.8 - Uncommon cancers of the kidney?????????????????????????????????????????????????????????????????????????? [Seite 1224]
18.20.9 - Conclusion?????????????????????????????????? [Seite 1224]
18.20.10 - Key references?????????????????????????????????????????? [Seite 1225]
18.21 - Chapter 97 Urothelial cancer [Seite 1227]
18.21.1 - Introduction and epidemiology???????????????????????????????????????????????????????????????????????? [Seite 1227]
18.21.2 - Pathobiology and molecular determinants???????????????????????????????????????????????????????????????????????????????????????????? [Seite 1227]
18.21.3 - Clinical presentation???????????????????????????????????????????????????????? [Seite 1229]
18.21.4 - Investigation and staging???????????????????????????????????????????????????????????????? [Seite 1229]
18.21.5 - Prognosis???????????????????????????????? [Seite 1230]
18.21.6 - Management of non-muscle-invasive bladder cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1230]
18.21.7 - Management of invasive bladder cancer???????????????????????????????????????????????????????????????????????????????????????? [Seite 1231]
18.21.8 - Metastatic bladder cancer???????????????????????????????????????????????????????????????? [Seite 1233]
18.21.9 - Uncommon histologic variants?????????????????????????????????????????????????????????????????????? [Seite 1233]
18.21.10 - Upper tract tumors?????????????????????????????????????????????????? [Seite 1234]
18.21.11 - Key references?????????????????????????????????????????? [Seite 1235]
18.22 - Chapter 98 Neoplasms of the prostate?????????????????????????????????????????????????????????????????????????????????????? [Seite 1237]
18.22.1 - Biology of prostate cancer?????????????????????????????????????????????????????????????????? [Seite 1237]
18.22.2 - Early detection of prostate cancer?????????????????????????????????????????????????????????????????????????????????? [Seite 1242]
18.22.3 - Staging of prostate cancer?????????????????????????????????????????????????????????????????? [Seite 1243]
18.22.4 - Outcomes of treatment for early disease???????????????????????????????????????????????????????????????????????????????????????????? [Seite 1249]
18.22.5 - Prostate cancer chemoprevention: Large trials???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1252]
18.22.6 - Algorithm for therapy: future directions?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1254]
18.22.7 - Locally advanced disease?????????????????????????????????????????????????????????????? [Seite 1254]
18.22.8 - Metastatic prostate cancer?????????????????????????????????????????????????????????????????? [Seite 1257]
18.22.9 - Histologic variants???????????????????????????????????????????????????? [Seite 1264]
18.22.10 - Clinical presentations?????????????????????????????????????????????????????????? [Seite 1265]
18.22.11 - Key references?????????????????????????????????????????? [Seite 1266]
18.23 - Chapter 99 Tumors of the penis and the urethra?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1269]
18.23.1 - Epidemiology and etiology???????????????????????????????????????????????????????????????? [Seite 1269]
18.23.2 - Diagnosis???????????????????????????????? [Seite 1269]
18.23.3 - Metastasis?????????????????????????????????? [Seite 1269]
18.23.4 - Tumor staging???????????????????????????????????????? [Seite 1270]
18.23.5 - Surgical treatment?????????????????????????????????????????????????? [Seite 1270]
18.23.6 - Tumor grade???????????????????????????????????? [Seite 1271]
18.23.7 - Pelvic lymphadenectomy?????????????????????????????????????????????????????????? [Seite 1271]
18.23.8 - Radiotherapy?????????????????????????????????????? [Seite 1271]
18.23.9 - Chemotherapy?????????????????????????????????????? [Seite 1272]
18.23.10 - Prognosis???????????????????????????????? [Seite 1272]
18.23.11 - Carcinoma of the urethra?????????????????????????????????????????????????????????????? [Seite 1272]
18.23.12 - References?????????????????????????????????? [Seite 1273]
18.24 - Chapter 100 Testis cancer???????????????????????????????????????????????????????????????? [Seite 1275]
18.24.1 - Epidemiology?????????????????????????????????????? [Seite 1275]
18.24.2 - Pathology???????????????????????????????? [Seite 1276]
18.24.3 - Clinical presentation???????????????????????????????????????????????????????? [Seite 1279]
18.24.4 - Staging???????????????????????????? [Seite 1281]
18.24.5 - Therapy???????????????????????????? [Seite 1281]
18.24.6 - Therapy for disseminated disease?????????????????????????????????????????????????????????????????????????????? [Seite 1286]
18.24.7 - Treatment of good-risk disseminated germ cell tumors?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1287]
18.24.8 - Treatment of patients with "poor-risk" disseminated disease???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1288]
18.24.9 - High-dose chemotherapy as primary treatment of poor-risk disease?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1289]
18.24.10 - Postchemotherapy surgery?????????????????????????????????????????????????????????????? [Seite 1289]
18.24.11 - High-dose chemotherapy as initial salvage therapy???????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1292]
18.24.12 - Treatment of multiply recurrent germ cell cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1293]
18.24.13 - Special situations?????????????????????????????????????????????????? [Seite 1293]
18.24.14 - Long-term toxicity of chemotherapy?????????????????????????????????????????????????????????????????????????????????? [Seite 1294]
18.24.15 - Long-term toxicity of radiation therapy???????????????????????????????????????????????????????????????????????????????????????????? [Seite 1296]
18.24.16 - Extragonadal germ cell tumors (EGCTs)???????????????????????????????????????????????????????????????????????????????????????? [Seite 1297]
18.24.17 - Unrecognized germ cell tumor syndrome???????????????????????????????????????????????????????????????????????????????????????? [Seite 1298]
18.24.18 - Key references?????????????????????????????????????????? [Seite 1299]
18.25 - Chapter 101 Neoplasms of the vulva and vagina???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1301]
18.25.1 - Cancer of the vulva???????????????????????????????????????????????????? [Seite 1301]
18.25.2 - Sentinel inguinal lymph node biopsy???????????????????????????????????????????????????????????????????????????????????? [Seite 1303]
18.25.3 - Treatment???????????????????????????????? [Seite 1304]
18.25.4 - Invasive carcinomas of the vagina???????????????????????????????????????????????????????????????????????????????? [Seite 1309]
18.25.5 - Clear cell adenocarcinoma of the vagina???????????????????????????????????????????????????????????????????????????????????????????? [Seite 1310]
18.25.6 - Rare vaginal tumors in young females?????????????????????????????????????????????????????????????????????????????????????? [Seite 1311]
18.25.7 - Key references?????????????????????????????????????????? [Seite 1312]
18.26 - Chapter 102 Neoplasms of the cervix???????????????????????????????????????????????????????????????????????????????????? [Seite 1313]
18.26.1 - Epidemiology?????????????????????????????????????? [Seite 1313]
18.26.2 - Histologic classification of epithelial tumors?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1315]
18.26.3 - Diagnosis and treatment of precancerous lesions???????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1317]
18.26.4 - Diagnosis and treatment of invasive lesions patterns of spread?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1321]
18.26.5 - Radiation therapy???????????????????????????????????????????????? [Seite 1326]
18.26.6 - Current practice by disease stage???????????????????????????????????????????????????????????????????????????????? [Seite 1329]
18.26.7 - Key references?????????????????????????????????????????? [Seite 1336]
18.27 - Chapter 103 Endometrial cancer?????????????????????????????????????????????????????????????????????????? [Seite 1337]
18.27.1 - Epidemiology?????????????????????????????????????? [Seite 1337]
18.27.2 - Risk factors?????????????????????????????????????? [Seite 1337]
18.27.3 - Pathology???????????????????????????????? [Seite 1338]
18.27.4 - Prognostic factors?????????????????????????????????????????????????? [Seite 1341]
18.27.5 - Treatment of primary disease?????????????????????????????????????????????????????????????????????? [Seite 1342]
18.27.6 - Treatment of recurrent disease?????????????????????????????????????????????????????????????????????????? [Seite 1344]
18.27.7 - Biologic therapies?????????????????????????????????????????????????? [Seite 1347]
18.27.8 - The future?????????????????????????????????? [Seite 1347]
18.27.9 - Key references?????????????????????????????????????????? [Seite 1347]
18.28 - Chapter 104 Epithelial ovarian, fallopian tube, and peritoneal cancer???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1349]
18.28.1 - Incidence, etiology, and epidemiology???????????????????????????????????????????????????????????????????????????????????????? [Seite 1349]
18.28.2 - Prevention?????????????????????????????????? [Seite 1350]
18.28.3 - Genetic predisposition?????????????????????????????????????????????????????????? [Seite 1350]
18.28.4 - Molecular, cellular, and clinical biology???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1352]
18.28.5 - Diagnosis???????????????????????????????? [Seite 1356]
18.28.6 - Screening???????????????????????????????? [Seite 1357]
18.28.7 - Staging???????????????????????????? [Seite 1358]
18.28.8 - Prognosis???????????????????????????????? [Seite 1359]
18.28.9 - Treatment of early-stage epithelial cancer?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1360]
18.28.10 - Treatment of advanced stage epithelial cancer???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1360]
18.28.11 - Treatment of recurrent epithelial cancer?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1366]
18.28.12 - Key references?????????????????????????????????????????? [Seite 1369]
18.29 - Chapter 105 Nonepithelial ovarian malignancies?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1371]
18.29.1 - Germ cell malignancies?????????????????????????????????????????????????????????? [Seite 1371]
18.29.2 - Dysgerminomas???????????????????????????????????????? [Seite 1372]
18.29.3 - Immature teratoma???????????????????????????????????????????????? [Seite 1375]
18.29.4 - Endodermal sinus tumor?????????????????????????????????????????????????????????? [Seite 1376]
18.29.5 - Embryonal carcinoma???????????????????????????????????????????????????? [Seite 1377]
18.29.6 - Choriocarcinoma of the ovary?????????????????????????????????????????????????????????????????????? [Seite 1377]
18.29.7 - Polyembryoma?????????????????????????????????????? [Seite 1377]
18.29.8 - Mixed germ cell tumor???????????????????????????????????????????????????????? [Seite 1377]
18.29.9 - Sex-cord-stromal tumors???????????????????????????????????????????????????????????? [Seite 1379]
18.29.10 - Granulosa-stromal cell tumors???????????????????????????????????????????????????????????????????????? [Seite 1379]
18.29.11 - Juvenile granulosa cell tumors?????????????????????????????????????????????????????????????????????????? [Seite 1381]
18.29.12 - Sertoli-Leydig cell tumors?????????????????????????????????????????????????????????????????? [Seite 1381]
18.29.13 - Uncommon ovarian cancers?????????????????????????????????????????????????????????????? [Seite 1381]
18.29.14 - Lipoid cell tumors?????????????????????????????????????????????????? [Seite 1381]
18.29.15 - Sarcomas?????????????????????????????? [Seite 1381]
18.29.16 - Small cell carcinomas???????????????????????????????????????????????????????? [Seite 1382]
18.29.17 - Metastatic tumors???????????????????????????????????????????????? [Seite 1382]
18.29.18 - Key references?????????????????????????????????????????? [Seite 1383]
18.30 - Chapter 106 Molar pregnancy and gestational trophoblastic neoplasia???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1385]
18.30.1 - Incidence???????????????????????????????? [Seite 1385]
18.30.2 - Risk factors?????????????????????????????????????? [Seite 1385]
18.30.3 - Histopathologic classification of GTN???????????????????????????????????????????????????????????????????????????????????????? [Seite 1385]
18.30.4 - Clinical presentation and diagnosis???????????????????????????????????????????????????????????????????????????????????? [Seite 1386]
18.30.5 - Staging and risk assessment???????????????????????????????????????????????????????????????????? [Seite 1386]
18.30.6 - Management of GTN???????????????????????????????????????????????? [Seite 1387]
18.30.7 - Management of low-risk GTN?????????????????????????????????????????????????????????????????? [Seite 1387]
18.30.8 - Management of high-risk GTN, stages II and III?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1387]
18.30.9 - Management of stage IV GTN?????????????????????????????????????????????????????????????????? [Seite 1388]
18.30.10 - Management of PSTT and ETT?????????????????????????????????????????????????????????????????? [Seite 1389]
18.30.11 - Results of therapy?????????????????????????????????????????????????? [Seite 1390]
18.30.12 - hCG follow-up and relapse???????????????????????????????????????????????????????????????? [Seite 1390]
18.30.13 - Quiescent GTN???????????????????????????????????????? [Seite 1390]
18.30.14 - Subsequent pregnancies?????????????????????????????????????????????????????????? [Seite 1390]
18.30.15 - Key references?????????????????????????????????????????? [Seite 1390]
18.31 - Chapter 107 Gynecologic sarcomas?????????????????????????????????????????????????????????????????????????????? [Seite 1393]
18.31.1 - Historical perspective?????????????????????????????????????????????????????????? [Seite 1393]
18.31.2 - Incidence and epidemiology?????????????????????????????????????????????????????????????????? [Seite 1393]
18.31.3 - Risk factors?????????????????????????????????????? [Seite 1393]
18.31.4 - Pathology???????????????????????????????? [Seite 1393]
18.31.5 - Endometrial stromal lesions???????????????????????????????????????????????????????????????????? [Seite 1393]
18.31.6 - Molecular and genetic alterations???????????????????????????????????????????????????????????????????????????????? [Seite 1393]
18.31.7 - Patterns of spread?????????????????????????????????????????????????? [Seite 1394]
18.31.8 - Clinical profile?????????????????????????????????????????????? [Seite 1394]
18.31.9 - Tumor biomarkers?????????????????????????????????????????????? [Seite 1394]
18.31.10 - Imaging studies???????????????????????????????????????????? [Seite 1394]
18.31.11 - Diagnosis???????????????????????????????? [Seite 1395]
18.31.12 - TNM and FIGO staging classification???????????????????????????????????????????????????????????????????????????????????? [Seite 1395]
18.31.13 - Prognostic factors and prognosis?????????????????????????????????????????????????????????????????????????????? [Seite 1395]
18.31.14 - Morcellation?????????????????????????????????????? [Seite 1395]
18.31.15 - LMS???????????????????? [Seite 1396]
18.31.16 - ESS???????????????????? [Seite 1396]
18.31.17 - Surgical treatment?????????????????????????????????????????????????? [Seite 1396]
18.31.18 - Postsurgical therapy for gynecologic sarcomas???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1396]
18.31.19 - Radiation oncology?????????????????????????????????????????????????? [Seite 1396]
18.31.20 - Chemotherapy?????????????????????????????????????? [Seite 1397]
18.31.21 - Combination chemotherapy?????????????????????????????????????????????????????????????? [Seite 1397]
18.31.22 - Adjuvant chemotherapy for limited disease???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1398]
18.31.23 - Hormone and biologic therapy?????????????????????????????????????????????????????????????????????? [Seite 1398]
18.31.24 - Mullerian adenosarcomas???????????????????????????????????????????????????????????? [Seite 1398]
18.31.25 - Nonuterine gynecologic sarcomas???????????????????????????????????????????????????????????????????????????? [Seite 1398]
18.31.26 - Key references?????????????????????????????????????????? [Seite 1399]
18.32 - Chapter 108 Neoplasms of the breast???????????????????????????????????????????????????????????????????????????????????? [Seite 1401]
18.32.1 - Epidemiology?????????????????????????????????????? [Seite 1401]
18.32.2 - Regulation of breast cancer growth?????????????????????????????????????????????????????????????????????????????????? [Seite 1406]
18.32.3 - Pathology???????????????????????????????? [Seite 1408]
18.32.4 - Prognostic factors?????????????????????????????????????????????????? [Seite 1411]
18.32.5 - Diagnosis and screening???????????????????????????????????????????????????????????? [Seite 1413]
18.32.6 - Risk and prevention???????????????????????????????????????????????????? [Seite 1417]
18.32.7 - Treatment of early-stage breast cancer?????????????????????????????????????????????????????????????????????????????????????????? [Seite 1420]
18.32.8 - Treatment for advanced breast cancer?????????????????????????????????????????????????????????????????????????????????????? [Seite 1451]
18.32.9 - Symptom management and survivorship???????????????????????????????????????????????????????????????????????????????????? [Seite 1470]
18.32.10 - Key references?????????????????????????????????????????? [Seite 1471]
18.33 - Chapter 109 Malignant melanoma?????????????????????????????????????????????????????????????????????????? [Seite 1473]
18.33.1 - Dermatologic principles in melanoma???????????????????????????????????????????????????????????????????????????????????? [Seite 1473]
18.33.2 - Clinical presentation???????????????????????????????????????????????????????? [Seite 1474]
18.33.3 - Pathologic features???????????????????????????????????????????????????? [Seite 1475]
18.33.4 - Clinicopathologic subtypes?????????????????????????????????????????????????????????????????? [Seite 1475]
18.33.5 - Less-common subtypes?????????????????????????????????????????????????????? [Seite 1475]
18.33.6 - Genetics and molecular pathology?????????????????????????????????????????????????????????????????????????????? [Seite 1476]
18.33.7 - Surgical management of melanoma???????????????????????????????????????????????????????????????????????????? [Seite 1477]
18.33.8 - The role of adjuvant therapy for stage II and III disease???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1480]
18.33.9 - Adjuvant radiation to the resected nodal basin?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1481]
18.33.10 - Uveal melanoma and rare melanomas of the eye?????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1482]
18.33.11 - Biology and therapy of advanced melanoma?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1483]
18.33.12 - Melanoma metastatic to the brain?????????????????????????????????????????????????????????????????????????????? [Seite 1489]
18.33.13 - Tumor-infiltrating lymphocyte (TIL) therapy in melanoma???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1489]
18.33.14 - Key references?????????????????????????????????????????? [Seite 1490]
18.34 - Chapter 110 Other skin cancers?????????????????????????????????????????????????????????????????????????? [Seite 1493]
18.34.1 - Ultraviolet radiation in the pathogenesis of skin cancers???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1493]
18.34.2 - Tumors arising from the epidermis???????????????????????????????????????????????????????????????????????????????? [Seite 1493]
18.34.3 - Tumors arising from dermis?????????????????????????????????????????????????????????????????? [Seite 1501]
18.34.4 - Tumors arising from appendages?????????????????????????????????????????????????????????????????????????? [Seite 1502]
18.34.5 - Benign cutaneous tumors associated with cancer syndromes?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1502]
18.34.6 - Metastatic tumors to the skin???????????????????????????????????????????????????????????????????????? [Seite 1503]
18.34.7 - Key references?????????????????????????????????????????? [Seite 1504]
18.35 - Chapter 111 Bone tumors???????????????????????????????????????????????????????????? [Seite 1507]
18.35.1 - Introduction?????????????????????????????????????? [Seite 1507]
18.35.2 - Evaluation?????????????????????????????????? [Seite 1507]
18.35.3 - Staging???????????????????????????? [Seite 1509]
18.35.4 - Biopsy?????????????????????????? [Seite 1509]
18.35.5 - Surgical margins?????????????????????????????????????????????? [Seite 1510]
18.35.6 - Limb salvage versus amputation?????????????????????????????????????????????????????????????????????????? [Seite 1511]
18.35.7 - Operative management of metastatic carcinoma, myeloma, and lymphoma???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1511]
18.35.8 - Reconstructive alternatives???????????????????????????????????????????????????????????????????? [Seite 1511]
18.35.9 - Radiotherapy for bone tumors?????????????????????????????????????????????????????????????????????? [Seite 1512]
18.35.10 - Medical management of bone tumors???????????????????????????????????????????????????????????????????????????????? [Seite 1513]
18.35.11 - Specific benign bone tumors???????????????????????????????????????????????????????????????????? [Seite 1513]
18.35.12 - Primary bone sarcomas???????????????????????????????????????????????????????? [Seite 1519]
18.35.13 - Metastatic disease to bone?????????????????????????????????????????????????????????????????? [Seite 1526]
18.35.14 - Myeloma???????????????????????????? [Seite 1527]
18.35.15 - Bone lymphoma???????????????????????????????????????? [Seite 1527]
18.35.16 - Congenital syndromes?????????????????????????????????????????????????????? [Seite 1527]
18.35.17 - Polyostotic fibrous dysplasia, McCune-Albright syndrome, and Mazabraud's syndrome???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1528]
18.35.18 - Multiple osteochondromatosis?????????????????????????????????????????????????????????????????????? [Seite 1528]
18.35.19 - Key references?????????????????????????????????????????? [Seite 1529]
18.36 - Chapter 112 Soft tissue sarcomas?????????????????????????????????????????????????????????????????????????????? [Seite 1531]
18.36.1 - Etiology?????????????????????????????? [Seite 1531]
18.36.2 - Screening???????????????????????????????? [Seite 1532]
18.36.3 - Clinical presentation, classification, and diagnosis?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1532]
18.36.4 - Staging and prognostic factors?????????????????????????????????????????????????????????????????????????? [Seite 1536]
18.36.5 - Treatment of localized primary disease of the extremities???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1538]
18.36.6 - Treatment of locally advanced disease???????????????????????????????????????????????????????????????????????????????????????? [Seite 1549]
18.36.7 - Treatment of metastatic disease???????????????????????????????????????????????????????????????????????????? [Seite 1549]
18.36.8 - Management of local recurrence?????????????????????????????????????????????????????????????????????????? [Seite 1554]
18.36.9 - Gastrointestinal stromal tumors???????????????????????????????????????????????????????????????????????????? [Seite 1555]
18.36.10 - Locally aggressive lesions: DFSPs, tenosynovial giant cell tumor (TGCT), perivascular epithelial cell tumor (PEComa) as targets for small molecule oral kinase inhibitors???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1556]
18.36.11 - Retroperitoneal sarcomas?????????????????????????????????????????????????????????????? [Seite 1556]
18.36.12 - Additional issues in STS management???????????????????????????????????????????????????????????????????????????????????? [Seite 1557]
18.36.13 - Immunotherapy for STS???????????????????????????????????????????????????????? [Seite 1558]
18.36.14 - Key references?????????????????????????????????????????? [Seite 1558]
18.37 - Chapter 113 The myelodysplastic syndrome?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1561]
18.37.1 - Etiology?????????????????????????????? [Seite 1531]
18.37.2 - Screening???????????????????????????????? [Seite 1532]
18.37.3 - Clinical presentation, classification, and diagnosis?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1532]
18.37.4 - Staging and prognostic factors?????????????????????????????????????????????????????????????????????????? [Seite 1536]
18.37.5 - Treatment of localized primary disease of the extremities???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1538]
18.37.6 - Treatment of locally advanced disease???????????????????????????????????????????????????????????????????????????????????????? [Seite 1549]
18.37.7 - Treatment of metastatic disease???????????????????????????????????????????????????????????????????????????? [Seite 1549]
18.37.8 - Management of local recurrence?????????????????????????????????????????????????????????????????????????? [Seite 1554]
18.37.9 - Gastrointestinal stromal tumors???????????????????????????????????????????????????????????????????????????? [Seite 1555]
18.37.10 - Locally aggressive lesions: DFSPs, tenosynovial giant cell tumor (TGCT), perivascular epithelial cell tumor (PEComa) as targets for small molecule oral kinase inhibitors???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1556]
18.37.11 - Retroperitoneal sarcomas?????????????????????????????????????????????????????????????? [Seite 1556]
18.37.12 - Additional issues in STS management???????????????????????????????????????????????????????????????????????????????????? [Seite 1557]
18.37.13 - Immunotherapy for STS???????????????????????????????????????????????????????? [Seite 1558]
18.37.14 - Key references?????????????????????????????????????????? [Seite 1558]
18.38 - Chapter 114 Acute myeloid leukemia in adults: mast cell leukemia and other mast cell neoplasms?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1577]
18.38.1 - Introduction?????????????????????????????????????? [Seite 1577]
18.38.2 - Pathogenesis and etiology???????????????????????????????????????????????????????????????? [Seite 1577]
18.38.3 - Prognosis???????????????????????????????? [Seite 1579]
18.38.4 - Morphologic classification and clinical and laboratory correlates???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1580]
18.38.5 - AML with recurrent genetic abnormalities?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1582]
18.38.6 - AML not otherwise specified???????????????????????????????????????????????????????????????????? [Seite 1584]
18.38.7 - Presenting signs and symptoms???????????????????????????????????????????????????????????????????????? [Seite 1587]
18.38.8 - Therapy: general overview???????????????????????????????????????????????????????????????? [Seite 1588]
18.38.9 - Induction therapy: general principles???????????????????????????????????????????????????????????????????????????????????????? [Seite 1588]
18.38.10 - Therapy of relapsed and refractory AML?????????????????????????????????????????????????????????????????????????????????????????? [Seite 1593]
18.38.11 - Therapy of acute promyelocytic leukemia (APL)???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1594]
18.38.12 - Other supportive care and therapeutic approaches?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1596]
18.38.13 - Minimal residual disease (MRD)?????????????????????????????????????????????????????????????????????????? [Seite 1597]
18.38.14 - Small-molecule inhibitors and other novel approaches?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1597]
18.38.15 - Complications???????????????????????????????????????? [Seite 1598]
18.38.16 - Central nervous system leukemia???????????????????????????????????????????????????????????????????????????? [Seite 1598]
18.38.17 - Mast cell leukemia and other mast cell neoplasms?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1599]
18.38.18 - Key references?????????????????????????????????????????? [Seite 1600]
18.39 - Chapter 115 Chronic myeloid leukemia?????????????????????????????????????????????????????????????????????????????????????? [Seite 1603]
18.39.1 - Historical perspective?????????????????????????????????????????????????????????? [Seite 1603]
18.39.2 - Incidence and epidemiology?????????????????????????????????????????????????????????????????? [Seite 1603]
18.39.3 - Risk factors?????????????????????????????????????? [Seite 1603]
18.39.4 - Pathology???????????????????????????????? [Seite 1603]
18.39.5 - Prognostic classification???????????????????????????????????????????????????????????????? [Seite 1604]
18.39.6 - Pathogenesis?????????????????????????????????????? [Seite 1605]
18.39.7 - Diagnosis???????????????????????????????? [Seite 1606]
18.39.8 - Staging and prognostic factors?????????????????????????????????????????????????????????????????????????? [Seite 1607]
18.39.9 - Treatment???????????????????????????????? [Seite 1607]
18.39.10 - Treatment options after failure of prior TKI?????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1608]
18.39.11 - Stem cell transplantation???????????????????????????????????????????????????????????????? [Seite 1609]
18.39.12 - Treatment recommendations in CML in 2015?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1609]
18.39.13 - Suvivorship and follow-up???????????????????????????????????????????????????????????????? [Seite 1610]
18.39.14 - Conclusion?????????????????????????????????? [Seite 1610]
18.39.15 - Key references?????????????????????????????????????????? [Seite 1610]
18.40 - Chapter 116 Acute lymphoblastic leukemia?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1613]
18.40.1 - Introduction?????????????????????????????????????? [Seite 1613]
18.40.2 - Epidemiology and etiology???????????????????????????????????????????????????????????????? [Seite 1613]
18.40.3 - Clinical presentation???????????????????????????????????????????????????????? [Seite 1613]
18.40.4 - Diagnosis of ALL?????????????????????????????????????????????? [Seite 1614]
18.40.5 - The therapy of ALL?????????????????????????????????????????????????? [Seite 1617]
18.40.6 - Salvage therapy???????????????????????????????????????????? [Seite 1621]
18.40.7 - Disease subtypes?????????????????????????????????????????????? [Seite 1621]
18.40.8 - Novel therapies???????????????????????????????????????????? [Seite 1622]
18.40.9 - Key references?????????????????????????????????????????? [Seite 1624]
18.41 - Chapter 117 Chronic lymphocytic leukemia?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1627]
18.41.1 - Chronic lymphocytic leukemia?????????????????????????????????????????????????????????????????????? [Seite 1627]
18.41.2 - Incidence and epidemiology?????????????????????????????????????????????????????????????????? [Seite 1627]
18.41.3 - Diagnosis of CLL?????????????????????????????????????????????? [Seite 1627]
18.41.4 - Pathogenesis and causation?????????????????????????????????????????????????????????????????? [Seite 1627]
18.41.5 - Immunobiology and immunophenotype of CLL cells?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1627]
18.41.6 - Clinical aspects?????????????????????????????????????????????? [Seite 1628]
18.41.7 - Clinical presentation???????????????????????????????????????????????????????? [Seite 1628]
18.41.8 - Natural history and terminal events???????????????????????????????????????????????????????????????????????????????????? [Seite 1629]
18.41.9 - Clinical staging and other prognostic features?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1630]
18.41.10 - Criteria predictive of disease course in the low- and intermediate-risk groups?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1630]
18.41.11 - Major prognostic markers?????????????????????????????????????????????????????????????? [Seite 1631]
18.41.12 - Treatment???????????????????????????????? [Seite 1631]
18.41.13 - Psychosocial aspects of CLL???????????????????????????????????????????????????????????????????? [Seite 1634]
18.41.14 - Unmet needs and future directions???????????????????????????????????????????????????????????????????????????????? [Seite 1634]
18.41.15 - Acknowledgments???????????????????????????????????????????? [Seite 1635]
18.41.16 - Key references?????????????????????????????????????????? [Seite 1635]
18.42 - Chapter 118 Hodgkin lymphoma?????????????????????????????????????????????????????????????????????? [Seite 1637]
18.42.1 - Introduction?????????????????????????????????????? [Seite 1637]
18.42.2 - History???????????????????????????? [Seite 1637]
18.42.3 - Epidemiology and etiology???????????????????????????????????????????????????????????????? [Seite 1637]
18.42.4 - Immunologic abnormalities in patients???????????????????????????????????????????????????????????????????????????????????????? [Seite 1638]
18.42.5 - Pathology???????????????????????????????? [Seite 1638]
18.42.6 - Immunophenotype and biology???????????????????????????????????????????????????????????????????? [Seite 1639]
18.42.7 - Staging???????????????????????????? [Seite 1641]
18.42.8 - Principles of treatment in classical Hodgkin lymphoma???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1641]
18.42.9 - Special populations???????????????????????????????????????????????????? [Seite 1644]
18.42.10 - Post-treatment surveillance???????????????????????????????????????????????????????????????????? [Seite 1644]
18.42.11 - Key references?????????????????????????????????????????? [Seite 1645]
18.43 - Chapter 119 Non-Hodgkin's lymphoma?????????????????????????????????????????????????????????????????????????????????? [Seite 1647]
18.43.1 - Epidemiology and etiology???????????????????????????????????????????????????????????????? [Seite 1647]
18.43.2 - Pathology, immunobiology, and natural history of NHL?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1647]
18.43.3 - Gray zone lymphoma?????????????????????????????????????????????????? [Seite 1652]
18.43.4 - Differential diagnosis and sites of disease at presentation???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1653]
18.43.5 - Staging and disease detection???????????????????????????????????????????????????????????????????????? [Seite 1654]
18.43.6 - Disease parameters that influence prognosis and assessment of disease response?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1654]
18.43.7 - Therapeutic approaches according to WHO classification?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1655]
18.43.8 - New therapeutic approaches for NHL?????????????????????????????????????????????????????????????????????????????????? [Seite 1660]
18.43.9 - Key references?????????????????????????????????????????? [Seite 1660]
18.44 - Chapter 120 Mycosis fungoides and Sézary syndrome [Seite 1661]
18.44.1 - Historical perspective?????????????????????????????????????????????????????????? [Seite 1661]
18.44.2 - Prognostic factors and biomarkers???????????????????????????????????????????????????????????????????????????????? [Seite 1661]
18.44.3 - Conclusions???????????????????????????????????? [Seite 1665]
18.44.4 - Key references?????????????????????????????????????????? [Seite 1665]
18.45 - Chapter 121 Plasma cell tumors?????????????????????????????????????????????????????????????????????????? [Seite 1667]
18.45.1 - Multiple myeloma?????????????????????????????????????????????? [Seite 1667]
18.45.2 - Diagnostic criteria???????????????????????????????????????????????????? [Seite 1667]
18.45.3 - Epidemiology?????????????????????????????????????? [Seite 1667]
18.45.4 - Clinical features???????????????????????????????????????????????? [Seite 1668]
18.45.5 - Laboratory features???????????????????????????????????????????????????? [Seite 1668]
18.45.6 - Biology???????????????????????????? [Seite 1668]
18.45.7 - Prognostic factors?????????????????????????????????????????????????? [Seite 1674]
18.45.8 - Complications???????????????????????????????????????? [Seite 1675]
18.45.9 - Treatment???????????????????????????????? [Seite 1677]
18.45.10 - Relapsed disease?????????????????????????????????????????????? [Seite 1683]
18.45.11 - Future directions???????????????????????????????????????????????? [Seite 1686]
18.45.12 - Other plasma cell dyscrasias?????????????????????????????????????????????????????????????????????? [Seite 1687]
18.45.13 - Immunoglobulin M monoclonal gammopathy?????????????????????????????????????????????????????????????????????????????????????????? [Seite 1687]
18.45.14 - Waldenström macroglobulinemia [Seite 1687]
18.45.15 - Heavy-chain diseases?????????????????????????????????????????????????????? [Seite 1688]
18.45.16 - Amyloidosis???????????????????????????????????? [Seite 1688]
18.45.17 - Key references?????????????????????????????????????????? [Seite 1689]
18.46 - Chapter 122 Myeloproliferative neoplasms: essential thrombocythemia, primary myelofibrosis, and polycythemia vera?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1691]
18.46.1 - Essential thrombocythemia???????????????????????????????????????????????????????????????? [Seite 1691]
18.46.2 - Primary myelofibrosis???????????????????????????????????????????????????????? [Seite 1694]
18.46.3 - Polycythemia vera???????????????????????????????????????????????? [Seite 1697]
18.46.4 - Key references?????????????????????????????????????????? [Seite 1700]
19 - Part 12 Management of Cancer Complications?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1703]
19.1 - Chapter 123 Neoplasms of unknown primary site???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1705]
19.1.1 - Pathologic evaluation???????????????????????????????????????????????????????? [Seite 1705]
19.1.2 - Clinical evaluation???????????????????????????????????????????????????? [Seite 1708]
19.1.3 - Treatment???????????????????????????????? [Seite 1710]
19.1.4 - Key references?????????????????????????????????????????? [Seite 1714]
19.2 - Chapter 124 Anorexia and cachexia???????????????????????????????????????????????????????????????????????????????? [Seite 1717]
19.2.1 - Introduction?????????????????????????????????????? [Seite 1717]
19.2.2 - Etiology and mechanisms???????????????????????????????????????????????????????????? [Seite 1717]
19.2.3 - Treatment???????????????????????????????? [Seite 1720]
19.2.4 - Future directions and summary???????????????????????????????????????????????????????????????????????? [Seite 1722]
19.2.5 - Key references?????????????????????????????????????????? [Seite 1722]
19.3 - Chapter 125 Antiemetic therapy?????????????????????????????????????????????????????????????????????????? [Seite 1725]
19.3.1 - Overview?????????????????????????????? [Seite 1725]
19.3.2 - Pathophysiology of nausea and vomiting?????????????????????????????????????????????????????????????????????????????????????????? [Seite 1725]
19.3.3 - Types of nausea and vomiting?????????????????????????????????????????????????????????????????????? [Seite 1726]
19.3.4 - Emetogenic chemotherapy???????????????????????????????????????????????????????????? [Seite 1726]
19.3.5 - Classes of antiemetics?????????????????????????????????????????????????????????? [Seite 1726]
19.3.6 - Recommendations for prevention and treatment of chemotherapy-induced emesis???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1729]
19.3.7 - Special situations?????????????????????????????????????????????????? [Seite 1730]
19.3.8 - Conclusions???????????????????????????????????? [Seite 1730]
19.3.9 - Key references?????????????????????????????????????????? [Seite 1730]
19.4 - Chapter 126 Neurologic complications of cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1733]
19.4.1 - Metastases?????????????????????????????????? [Seite 1733]
19.4.2 - Cranial and peripheral nerve metastases???????????????????????????????????????????????????????????????????????????????????????????? [Seite 1739]
19.4.3 - Nonmetastatic complications of cancer therapy???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1741]
19.4.4 - Cerebrovascular complications of cancer???????????????????????????????????????????????????????????????????????????????????????????? [Seite 1745]
19.4.5 - Paraneoplastic neurologic syndromes???????????????????????????????????????????????????????????????????????????????????? [Seite 1746]
19.4.6 - References?????????????????????????????????? [Seite 1746]
19.5 - Chapter 127 Dermatologic complications of cancer chemotherapy???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1749]
19.5.1 - Drug hypersensitivity reactions???????????????????????????????????????????????????????????????????????????? [Seite 1749]
19.5.2 - Targeted cancer therapeutics?????????????????????????????????????????????????????????????????????? [Seite 1749]
19.5.3 - Immunomodulators?????????????????????????????????????????????? [Seite 1752]
19.5.4 - Alopecia?????????????????????????????? [Seite 1753]
19.5.5 - Stomatitis?????????????????????????????????? [Seite 1753]
19.5.6 - Nail reactions?????????????????????????????????????????? [Seite 1753]
19.5.7 - Extravasation reactions???????????????????????????????????????????????????????????? [Seite 1753]
19.5.8 - Pigmentary changes?????????????????????????????????????????????????? [Seite 1754]
19.5.9 - Radiation-associated reactions?????????????????????????????????????????????????????????????????????????? [Seite 1754]
19.5.10 - Acral reactions???????????????????????????????????????????? [Seite 1756]
19.5.11 - Cutaneous eruption of lymphocyte recovery???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1757]
19.5.12 - Key references?????????????????????????????????????????? [Seite 1758]
19.6 - Chapter 128 Skeletal complications?????????????????????????????????????????????????????????????????????????????????? [Seite 1759]
19.6.1 - Introduction?????????????????????????????????????? [Seite 1759]
19.6.2 - Evaluation of a patient with bone lesions???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1759]
19.6.3 - Solitary lesions of bone?????????????????????????????????????????????????????????????? [Seite 1759]
19.6.4 - Options for treatment of skeletal lesions???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1760]
19.6.5 - Principles of pathologic fracture treatment???????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1761]
19.6.6 - Intramedullary nailing?????????????????????????????????????????????????????????? [Seite 1761]
19.6.7 - Plate and screw fixation?????????????????????????????????????????????????????????????? [Seite 1762]
19.6.8 - Arthroplasty?????????????????????????????????????? [Seite 1762]
19.6.9 - Megaprostheses?????????????????????????????????????????? [Seite 1763]
19.6.10 - Treatment of periacetabular lesions???????????????????????????????????????????????????????????????????????????????????? [Seite 1764]
19.6.11 - Resection without reconstruction?????????????????????????????????????????????????????????????????????????????? [Seite 1764]
19.6.12 - Spine lesions???????????????????????????????????????? [Seite 1764]
19.6.13 - Treatment of painful metastases and impending fractures???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1767]
19.6.14 - References?????????????????????????????????? [Seite 1767]
19.7 - Chapter 129 Hematologic complications and blood bank support?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1769]
19.7.1 - Causes of pancytopenia?????????????????????????????????????????????????????????? [Seite 1769]
19.7.2 - Abnormalities of red cells and red cell support???????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1769]
19.7.3 - Leukopenia and white cell support???????????????????????????????????????????????????????????????????????????????? [Seite 1770]
19.7.4 - Thrombocytopenia and platelet support???????????????????????????????????????????????????????????????????????????????????????? [Seite 1771]
19.7.5 - Abnormalities in platelet function?????????????????????????????????????????????????????????????????????????????????? [Seite 1771]
19.7.6 - Single- and multiple-donor platelets?????????????????????????????????????????????????????????????????????????????????????? [Seite 1771]
19.7.7 - Clinical and laboratory assessment of the effectiveness of platelet transfusion???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1772]
19.7.8 - Other therapeutic modalities?????????????????????????????????????????????????????????????????????? [Seite 1772]
19.7.9 - Effects of transfusion on the immune system???????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1773]
19.7.10 - Transfusion-associated GVHD???????????????????????????????????????????????????????????????????? [Seite 1773]
19.7.11 - Definition of those at risk???????????????????????????????????????????????????????????????????? [Seite 1773]
19.7.12 - Strategies for prevention???????????????????????????????????????????????????????????????? [Seite 1773]
19.7.13 - Transfusion-related infectious diseases???????????????????????????????????????????????????????????????????????????????????????????? [Seite 1773]
19.7.14 - Human immunodeficiency virus (HIV)?????????????????????????????????????????????????????????????????????????????????? [Seite 1774]
19.7.15 - Human T-cell lymphotrophic virus type 1???????????????????????????????????????????????????????????????????????????????????????????? [Seite 1774]
19.7.16 - Creutzfeldt-Jakob disease???????????????????????????????????????????????????????????????? [Seite 1775]
19.7.17 - Conclusion?????????????????????????????????? [Seite 1775]
19.7.18 - Key references?????????????????????????????????????????? [Seite 1775]
19.8 - Chapter 130 Coagulopathic complications of cancer patients?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1777]
19.8.1 - Physiology of normal hemostasis???????????????????????????????????????????????????????????????????????????? [Seite 1777]
19.8.2 - Relationship of coagulation system, inflammation, and cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1778]
19.8.3 - Microparticles?????????????????????????????????????????? [Seite 1778]
19.8.4 - Bleeding disorders?????????????????????????????????????????????????? [Seite 1778]
19.8.5 - Coagulation factor deficiencies???????????????????????????????????????????????????????????????????????????? [Seite 1781]
19.8.6 - Drug effects (L-asparaginase)???????????????????????????????????????????????????????????????????????? [Seite 1781]
19.8.7 - Acute promyelocytic leukemia?????????????????????????????????????????????????????????????????????? [Seite 1781]
19.8.8 - Thrombotic complications?????????????????????????????????????????????????????????????? [Seite 1781]
19.8.9 - Anticancer effects of anticoagulation treatment???????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1783]
19.8.10 - Heparin-induced thrombocytopenia (HIT)?????????????????????????????????????????????????????????????????????????????????????????? [Seite 1783]
19.8.11 - Thrombotic microangiopathies?????????????????????????????????????????????????????????????????????? [Seite 1784]
19.8.12 - Arterial thrombosis and nonbacterial thrombotic endocarditis?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1784]
19.8.13 - Disseminated intravascular coagulation (DIC)?????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1784]
19.8.14 - Drugs for treatment of bleeding and thrombotic disorders?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1785]
19.8.15 - Key references?????????????????????????????????????????? [Seite 1786]
19.9 - Chapter 131 Urologic complications?????????????????????????????????????????????????????????????????????????????????? [Seite 1787]
19.9.1 - Introduction?????????????????????????????????????? [Seite 1787]
19.9.2 - Urinary tract obstruction???????????????????????????????????????????????????????????????? [Seite 1787]
19.9.3 - Cystitis and nephritis?????????????????????????????????????????????????????????? [Seite 1788]
19.9.4 - Diagnosis, treatment, and prevention of nephrotoxicity of cancer therapeutic agents???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1789]
19.9.5 - Key references?????????????????????????????????????????? [Seite 1794]
19.10 - Chapter 132 Cardiac complications???????????????????????????????????????????????????????????????????????????????? [Seite 1795]
19.10.1 - Evaluation of the cardiovascular system in the cancer patient???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1795]
19.10.2 - Metastatic involvement of cardiac structures?????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1796]
19.10.3 - Cardiac effects of mediator release, high output states, and infiltrative disorders in cancer patients?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1799]
19.10.4 - Cardiac dysrhythmia in the cancer patient???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1802]
19.10.5 - Cardiac complications of cancer treatment???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1802]
19.10.6 - References?????????????????????????????????? [Seite 1812]
19.11 - Chapter 133 Respiratory complications???????????????????????????????????????????????????????????????????????????????????????? [Seite 1813]
19.11.1 - Malignant airway obstruction?????????????????????????????????????????????????????????????????????? [Seite 1813]
19.11.2 - Malignant pleural effusions???????????????????????????????????????????????????????????????????? [Seite 1814]
19.11.3 - Postsurgical respiratory insufficiency?????????????????????????????????????????????????????????????????????????????????????????? [Seite 1819]
19.11.4 - Chemotherapy-induced lung injury?????????????????????????????????????????????????????????????????????????????? [Seite 1820]
19.11.5 - Pulmonary complications of thoracic radiation: Radiation pneumonitis and fibrosis???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1827]
19.11.6 - Pulmonary complications of hematopoietic stem cell transplantation?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1828]
19.11.7 - Pneumonia???????????????????????????????? [Seite 1830]
19.11.8 - Venous thromboembolism?????????????????????????????????????????????????????????? [Seite 1831]
19.11.9 - Pulmonary hypertension in the cancer patient?????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1831]
19.11.10 - Sleep disorders in cancer patients?????????????????????????????????????????????????????????????????????????????????? [Seite 1832]
19.11.11 - Pulmonary rehabilitation?????????????????????????????????????????????????????????????? [Seite 1833]
19.11.12 - Acute respiratory failure???????????????????????????????????????????????????????????????? [Seite 1833]
19.11.13 - Key references?????????????????????????????????????????? [Seite 1836]
19.12 - Chapter 134 Gastrointestinal and hepatic complications in cancer patients???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1839]
19.12.1 - Esophageal disorders?????????????????????????????????????????????????????? [Seite 1839]
19.12.2 - Diarrhea?????????????????????????????? [Seite 1842]
19.12.3 - Colitis???????????????????????????? [Seite 1844]
19.12.4 - Intestinal manifestations of graft-versus-host disease?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1846]
19.12.5 - Hepatic complications of cancer treatment???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1847]
19.12.6 - Other GI complications of cancer therapy?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1850]
19.12.7 - Key references?????????????????????????????????????????? [Seite 1851]
19.13 - Chapter 135 Oral complications of cancer and their treatment?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1853]
19.13.1 - Pretreatment assessment???????????????????????????????????????????????????????????? [Seite 1853]
19.13.2 - Oral complications of radiotherapy?????????????????????????????????????????????????????????????????????????????????? [Seite 1854]
19.13.3 - Oral complications of chemotherapy?????????????????????????????????????????????????????????????????????????????????? [Seite 1858]
19.13.4 - Oral complications associated with HSCT???????????????????????????????????????????????????????????????????????????????????????????? [Seite 1862]
19.13.5 - Key references?????????????????????????????????????????? [Seite 1863]
19.14 - Chapter 136 Gonadal complications???????????????????????????????????????????????????????????????????????????????? [Seite 1865]
19.14.1 - Historical background???????????????????????????????????????????????????????? [Seite 1865]
19.14.2 - Assessment of gonadal function after gonadotoxic therapy?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1865]
19.14.3 - Effects of cytotoxic chemotherapy on gonadal function???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1866]
19.14.4 - Fertility following high-dose chemotherapy?????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1869]
19.14.5 - Effects of radiation therapy on gonadal function?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1869]
19.14.6 - Effects of targeted therapies on gonadal function???????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1869]
19.14.7 - Protective measures???????????????????????????????????????????????????? [Seite 1870]
19.14.8 - Outcomes of pregnancy???????????????????????????????????????????????????????? [Seite 1871]
19.14.9 - Psychosocial issues???????????????????????????????????????????????????? [Seite 1872]
19.14.10 - Key references?????????????????????????????????????????? [Seite 1872]
19.15 - Chapter 137 Sexual dysfunction?????????????????????????????????????????????????????????????????????????? [Seite 1875]
19.15.1 - Historical perspective?????????????????????????????????????????????????????????? [Seite 1875]
19.15.2 - Incidence and epidemiology-local and worldwide?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1875]
19.15.3 - Risk factors-premorbid sexual function, cancer treatments, and behavioral characteristics???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1876]
19.15.4 - Prevention-surgical, medical, behavioral?????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1876]
19.15.5 - Screening???????????????????????????????? [Seite 1876]
19.15.6 - Diagnosis???????????????????????????????? [Seite 1877]
19.15.7 - Prognostic factors?????????????????????????????????????????????????? [Seite 1877]
19.15.8 - Multidisciplinary care?????????????????????????????????????????????????????????? [Seite 1877]
19.15.9 - Psychosocial factors and management???????????????????????????????????????????????????????????????????????????????????? [Seite 1877]
19.15.10 - Survivorship and follow-up?????????????????????????????????????????????????????????????????? [Seite 1877]
19.15.11 - Unmet needs, future directions, and conclusions???????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1877]
19.15.12 - Key references?????????????????????????????????????????? [Seite 1878]
19.16 - Chapter 138 Endocrine complications and paraneoplastic syndromes?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1881]
19.16.1 - Introduction?????????????????????????????????????? [Seite 1881]
19.16.2 - Endocrine complications???????????????????????????????????????????????????????????? [Seite 1881]
19.16.3 - Endocrine paraneoplastic syndromes ("ectopic" hormone production)???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1890]
19.16.4 - Key references?????????????????????????????????????????? [Seite 1895]
19.17 - Chapter 139 Infections in patients with cancer?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1897]
19.17.1 - Infections primarily associated with neutropenia?????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1897]
19.17.2 - Infections primarily associated with impaired cellular and humoral immunity???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1897]
19.17.3 - Spectrum of infection???????????????????????????????????????????????????????? [Seite 1898]
19.17.4 - Fungal infections???????????????????????????????????????????????? [Seite 1901]
19.17.5 - Viral infections?????????????????????????????????????????????? [Seite 1903]
19.17.6 - Special situations?????????????????????????????????????????????????? [Seite 1904]
19.17.7 - Perianal infections???????????????????????????????????????????????????? [Seite 1905]
19.17.8 - Catheter-related infections???????????????????????????????????????????????????????????????????? [Seite 1905]
19.17.9 - Therapy of infections in patients with neutropenia?????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1905]
19.17.10 - Duration of therapy???????????????????????????????????????????????????? [Seite 1906]
19.17.11 - Infection prevention?????????????????????????????????????????????????????? [Seite 1907]
19.17.12 - Antifungal and antiviral prophylaxis?????????????????????????????????????????????????????????????????????????????????????? [Seite 1907]
19.17.13 - Antimicrobial stewardship???????????????????????????????????????????????????????????????? [Seite 1908]
19.17.14 - Perspectives?????????????????????????????????????? [Seite 1908]
19.17.15 - Key references?????????????????????????????????????????? [Seite 1908]
19.18 - Chapter 140 Oncologic emergencies???????????????????????????????????????????????????????????????????????????????? [Seite 1911]
19.18.1 - Introduction?????????????????????????????????????? [Seite 1911]
19.18.2 - Approach to acutely III cancer patients???????????????????????????????????????????????????????????????????????????????????????????? [Seite 1911]
19.18.3 - Circulatory oncologic emergencies???????????????????????????????????????????????????????????????????????????????? [Seite 1911]
19.18.4 - Respiratory oncologic emergencies???????????????????????????????????????????????????????????????????????????????? [Seite 1920]
19.18.5 - Neurologic oncologic emergencies?????????????????????????????????????????????????????????????????????????????? [Seite 1923]
19.18.6 - Other oncologic emergencies???????????????????????????????????????????????????????????????????? [Seite 1925]
19.18.7 - Key references?????????????????????????????????????????? [Seite 1929]
20 - Part 13 The Future of Oncology?????????????????????????????????????????????????????????????????????????? [Seite 1931]
20.1 - Chapter 141 A vision for twenty-first century healthcare?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1933]
20.1.1 - A vision for healthcare???????????????????????????????????????????????????????????? [Seite 1933]
20.1.2 - Quantifying wellness and demystifying disease???????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1933]
20.1.3 - The emergence of P4 medicine?????????????????????????????????????????????????????????????????????? [Seite 1933]
20.1.4 - The early stages?????????????????????????????????????????????? [Seite 1933]
20.1.5 - The book of life-four levels of biological information?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1934]
20.1.6 - Systems medicine: a tipping point???????????????????????????????????????????????????????????????????????????????? [Seite 1935]
20.1.7 - P4 medicine: a revolution in healthcare???????????????????????????????????????????????????????????????????????????????????????????? [Seite 1936]
20.1.8 - P4 medicine: quantifying wellness and demystifying disease?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1937]
20.1.9 - A pilot wellness program?????????????????????????????????????????????????????????????? [Seite 1937]
20.1.10 - 100,000 Person Wellness Project???????????????????????????????????????????????????????????????????????????? [Seite 1937]
20.1.11 - Importance of data accessibility from the longitudinal 100K Wellness Project?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1938]
20.1.12 - Scaling up?????????????????????????????????? [Seite 1938]
20.1.13 - Hundred Person Wellness Project???????????????????????????????????????????????????????????????????????????? [Seite 1938]
20.1.14 - Hundred Pioneer pilot study results???????????????????????????????????????????????????????????????????????????????????? [Seite 1938]
20.1.15 - Benefits of the 100,000 (100K) person and 107 Pioneer wellness studies for healthcare???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1939]
20.1.16 - How do we plan to proceed??????????????????????????????????????????????????????????????????? [Seite 1939]
20.1.17 - Systems medicine and cancer: a postscript???????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1939]
20.1.18 - The democratization of wellness and healthcare?????????????????????????????????????????????????????????????????????????????????????????????????????????? [Seite 1940]
20.1.19 - Acknowledgments???????????????????????????????????????????? [Seite 1940]
20.1.20 - References?????????????????????????????????? [Seite 1940]
21 - Index???????????????????????? [Seite 1943]
22 - EULA [Seite 2004]

Dateiformat: PDF
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Bitte beachten Sie bei der Verwendung der Lese-Software Adobe Digital Editions: wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

240,99 €
inkl. 7% MwSt.
Download / Einzel-Lizenz
PDF mit Adobe-DRM
siehe Systemvoraussetzungen
E-Book bestellen